LinköpingUniversityMedicalDissertationNo.1553

Responsetoneoadjuvanttreatmentinrectalcancersurgery

PerLoftås

Department for Clinical and Experimental Medicine, Linköping University, Linköping Division of Surgery

The Faculty of Medicine and Health Sciences, Linköping University SE-581 85 Linköping, Sweden

2016

Copyright©PerLoftås,2016Per.loftas@liu.seCover“5-FU-ckCancer”Copyright©NinaLönn,2016 ISBN:978-91-7685-638-3ISSN0345-0082PrintedinSwedenbyLiU-Tryck,Linköping2016

”Writing a book is an adventure. To begin with it is a toy and an amusement. Then it becomes a mistress, then it becomes a master, then it becomes a tyrant. The last phase is that just as you are about to be reconciled to your servitude, you kill the

monster and fling him to the public.” SirWinstonChurchill.

Tomyfamily

Contents1. Abstract……………………………………………………………. 9

2. Listofpublications…………………………………………... 11

3. Abbreviations………………………………………………… 13

4. SummaryinSwedish……………………………………….. 15

5. Introductionandbackground

Introduction……………………………………………………. 19

Molecularbackgroundtocolorectalcancer………. 21

Radiationtherapy……………………………………………. 25

Neoadjuvantchemotherapy…………………………….. 27Rectalcancerflowchart…………………………………... 28

Surgicaltreatment…………………………………………... 29

Magneticresonanceimaginginrectalcancer.…… 31

6. Aimsofthethesis……………………………………………. 33

7. Patientsandmethods

StudyI……………………………………………………………. 35StudyII…………………………………………………………… 37StudyIII………………………………………………………….. 39StudyIV………………………………………………………….. 41

8. Resultsanddiscussion

StudyI……………………………………………………………. 43StudyII…………………………………………………………… 45StudyIII………………………………………………………….. 47StudyIV………………………………………………………….. 51

9. Generaldiscussionandfutureperspectives……... 53

10. Acknowledgements…………………………………………. 57

11. References……………………………………………………… 61

12. StudiesI-IV…………………………………………………….. 67

9

AbstractRectalcancerisoneofthethreemostcommonmalignanciesinSwedenwithanannualincidenceofabout2000cases.Currenttreatmentconsistsofsurgicalresectionoftherectumincludingtheloco-regionallymphnodesinthemesorectum.Inadvancedcases,neoadjuvantchemo-radiotherapy(CRT)priortotheoperativetreatmentreduceslocalrecurrencesandenablessurgery.Theneoadjuvanttreatmentcanalsoeradicatethetumourcompletely,i.e.completeresponse.Thisresearchprojectwasdesignedtoinvestigatetheeffectsofpreoperativeradiotherapy/CRTandanalyzemethodstopredictresponsetoCRT.StudyIinvestigatedtheexpressionoftheFXYD-3proteinwithimmunohistochemistryinrectalcancer,withorwithoutpreoperativeradiotherapy.Theresultsfromthetotalcohortshowedthat,strongFXYD-3expressionwascorrelatedtoinfiltrativetumourgrowth(p=0.02).Intheradiotherapygroup,strongFXYD-3expressionwasrelatedtoanunfavourableprognosis(p=0.02).TumourswithstrongFXYD-3expressionhadlesstumournecrosis(p=0.02)afterradiotherapy.FXYD-3expressionintheprimarytumourwasincreasedcomparedtonormalmucosa(p=0.008).WeconcludedthatFXYD-3expressionwasaprognosticfactorinpatientsreceivingpreoperativeradiotherapyforrectalcancer.StudyIIinvestigatedFXYD-3expressionintumoursthatdevelopedlocalrecurrencesfollowingsurgeryandcomparedthiswithexpressionintumoursthatdidnotdeveloplocalrecurrences.TherewasnodifferenceintheexpressionofFXYD-3betweenthegroupthatdevelopedlocalrecurrencesandthegroupthatdidnotdeveloplocalrecurrences.TherewasnodifferenceinsurvivalbetweenthosewithstrongorweakFXYD-3expression.Weconcludedthatthisstudycouldnotconfirmthefindingsfromstudy1i.e.thatFXYD-3expressionhasprognosticsignificanceinrectalcancer.StudyIIIwasaregister-basedstudyontheincidenceandeffectsofcompleteresponsetoneoadjuvanttreatment.EightpercentofthepatientswithadequateCRTtoachievecompleteresponsealsohadacompletehistologicalresponseoftheluminaltumorintheresectedbowel.Sixteenpercentofthatgrouphadremaininglymphnodemetastasesintheoperativespecimen.Chemotherapytogetherwithradiotherapydoubledthechanceofcompleteresponseintheluminaltumour.Patientswithremaininglymphnodemetastaseshadalowersurvivalratecomparedtothosewithout.Weconcludedthatresidualnodalinvolvementafterneoadjuvanttreatmentwasanimportantfactorforreducedsurvivalaftercompleteresponseintheluminaltumour.StudyIVfolloweduptheresultsfromthepreviousstudybyre-evaluatingmagneticresonanceimaging(MRI)-imagesinpatientswithcompletetumourresponse.TwoexperiencedMRIradiologistsperformedblindedre-stagingofpostCRTMR-imagesfrompatientswithcompleteresponseintheluminaltumour.Onegroupwithlymphnodemetastasesandanotheronewithoutwerestudiedandtheresultscomparedwiththepathologyreports.Thesensitivity,specificity,andpositiveandnegativepredictedvaluesforcorrectstagingofpositivelymphnodeswas37%, 84%, 70% and 57%. Thesizeofthelargestlymphnode(4.5mm,p=0.04)seemedtoindicatepresenceofatumourpositivelymphnode.WeconcludedthatMRIcouldn’tcorrectlystagepatientsforlymphnodemetastasesinpatientswithcompleteresponsetoCRTintheluminaltumour.

10

11

Listofpublications 1. LoftåsP,ÖnnesjöS,WidegrenE,AdellG,KayedH,KleeffJ,ZentgrafH,SunX-F.ExpressionofFXYD-3isanIndependentPrognosticFactorinRectalCancerPatientsWithPreoperativeRadiotherapy.InternationalJournalofRadiationOncologyBiologyPhysics2009;75(1):137-142.2. LoftasP,ArbmanG,SunXF,EdlerD,SykE,HallbookO.FXYD-3expressioninrelationtolocalrecurrenceofrectalcancer.Radiationoncologyjournal2016;34(1):52-58.3. LoftasP,ArbmanG,FomichovV,HallbookO.Nodalinvolvementinluminalcompleteresponseafterneoadjuvanttreatmentforrectalcancer.Europeanjournalofsurgicaloncology:thejournaloftheEuropeanSocietyofSurgicalOncologyandtheBritishAssociationofSurgicalOncology2016;42(6):801-807.4.LoftåsP,Sturludóttir,HallböökO,AlmlövK,ArbmanG,BlomqvistL.AssessmentofremainingtumourpositivelymphnodeswithMRIinpatientswithcompleteluminalresponseafterneoadjuvanttreatmentofrectalcancerInmanuscript.

12

13

Abbreviations

• 3-D ThreeDimensional• 5-FU 5-Fluorouracil• AJCC AmericanJointCommitteeonCancer• AR AnteriorResection• APR AbdominoPerinealResection.• ATP AdenosinTriPhosphate• C.I ConfidenceInterval• cCR ClinicalCompleteResponse• CRM CircumferentialResectionMargin• CRT Chemo-RadioTherapy• DAB DiAmineBenzidinetetrahydrochloride• DCE DynamicContrastEnhanced• EMVI ExtraMuralVenousInvasion• FXYD-3 Probablyeponymfor“fixedID”• Gy Gray• IQR InterQuartileRange• kD/kDa kiloDalton• LCR LuminalCompleteResponse• LR LocalRecurrence• LRT LongtermRadiotherapyTreatment• MAT-8 MammaryTumourProtein• MCF-7 MichiganCancerFoundation• MRI MagneticResonanceImaging• mRNA MessengerRiboNukleinAcid• MDT MultiDisciplinaryTeam• MV MegaVolt• NCR NationalCancerRegistry• NPV NegativePredictiveValue• p21 Protein21• p53 Protein53• P73 Protein73• PBS PhosphateBufferedSaline• pCR pathologicCompleteResponse• PPV PositivePredictiveValue• PRL PhosphataseofRegeneratingLiver• R0 PathologicallyconfirmedRadicalResection• RT Radiotherapy• SCRCR SwedishColoRectalCancerRegister• SPSS StatisticalPackagefortheSocialScience• SRT Short-termRadiotherapyTreatment• T Tesla/Tumour• T1-T2-weigted Tissue-weighted• TME TotalMesorectalExcision• TNM Tumour,Node,Metastasis(classification)

14

15

Sammanfattningpåsvenska Ändtarms-ochtjocktarmscancerärtvåavdevanligastecancerformernaiSverigeochivästvärlden.Ändtarmscancerdrabbarvanligtvisindivideriåldern70-75år,mensjukdomenkanävendrabbabetydligtyngre.Denärnågotvanligarehosmänänhoskvinnor.Precissomfördeflestaandracancersjukdomarfinnsingenenskildorsaktillattmandrabbasavsjukdomen,menvästerländskkost,vissakroniskatarmsjukdomarsamtärftlighetkanökarisken.Somallaandracancersjukdomarkanändtarmscancerspridasigikroppenmeddottertumörer,vanligtvisileverochlungor.Iundantagsfallåterkommertumörenävenibäckenetefterbotandebehandling,såkallatlokalrecidiv.Behandlingenförändtarmscancerharlängevaritkirurgidåhelaellerdelaravändtarmenopererasbort.Iblandtasocksåändtarmsöppningenbortochpatientenfårenpermanenttarmöppningpåmagen,enstomi.Ompatientenstrålbehandlasföreoperationenminskarriskenattfååterfallibäckenet.Strålningenminskarocksåtumörensstorlekvilketgerbättreförutsättningarföroperation.Behandlingmedbådecellgifterochstrålningäreffektivareochkanävenpåverkatumörcellersomtagitsigvidareikroppen.Kombinationenavstrålningochcellgifteräriblandsålyckadatthelatumörenochäventumörsomspriditsigtillderegionalalymfkörtlarnaförsvinnerheltinnandenplaneradeoperationen.Hittillsharpatientenändåblivitopereradeftersomdetansesvaradensäkrastemetoden.Bådestrålningochcellgifterharsvåraochmångagångerlivslångabiverkningarochdessamåstevägasmotvinsternamedbehandlingen.Detinnebärattbarapatientermedmeravanceradsjukdomfårförbehandlingmedstrålningoch/ellercellgiftereftersomnyttanavbehandlingenidefallenvägertyngreänbiverkningarna.Denförstastudienfokuseradepåettprotein,FXYD-3.Allatumörerinnehållerintedettaprotein,medanendelharhögahalteravproteinet,andraavsevärtlägre.Syftetmedstudienvarattundersökaomtumörersomharhögahalteravdettaproteinharensämreprognosochdärmedettstörrebehovavstrålbehandling.StudienvisadeattFXYD-3varvanligareitumörvävnadäninormalvävnad.TumörersomhademycketFXYD-3växteocksåaggressivareäntumörersomintehadesåhögahalteravproteinet.HosdepatientersomstråladesinnanoperationenkundemanseattmycketFXYD-3itumörenmedfördesämreöverlevnadochsämresvarpåstrålbehandlingen.Dessaskillnaderkundemaninteseidenpatientgruppsominteficknågonstrålbehandling.

16

TolkningenavdessaresultatärattFXYD-3verkarkunnatydliggöravilkapatientersomharenmeraggressivsjukdomochsomdärförintesvararlikabrapåstrålbehandlingochdärmedocksåfårensämreprognos.DenandrastudienärenfortsättningpådenförstadärvivillebekräftaattdepatientersomharFXYD-3itumörenkanförutsägashasämreresultatavstrålbehandling.Dådettydligasteresultatetavstrålbehandlinginnanoperationvisatsigvaraenminskningavantaletåterfallibäckenet,lokalrecidiv,valdeviattanalyseratumörersomutvecklatlokalrecidiv.IdenhärstudiensamarbetadevimedKarolinskaInstitutetiStockholmsomtidigarestuderatsammapatientgrupp.VistuderademängdenFXYD-3hospatientermedlokalrecidiv,ochjämfördedemmedengrupppatientersominteutvecklatlokalrecidiv.VikundeintebekräftaatttumörermedmycketFXYD-3ihögregradriskeraråterfalltillbäckenet.TolkningenförsvårasdelsavattdetvarfåpatientermedmycketFXYD-3itumörensomfickstrålningochävenutveckladelokalrecidiv.Idenhärstudienkundeviintebekräftaresultatetidenförstastudien.Identredjestudienvaldeviattstuderadenpatientgruppsomfickettsåbraresultatavstrål-ochcellgiftsbehandlingeninnanoperationatthelatumörenförsvann,såkalladcompleteresponse.Vivillegenomregisterforskningtaredaförekomstochprognosfördessapatientersomopereradesutanattmanfannnågonkvarvarandetumörvidmikroskopiskundersökningavdenbortopereradetarmen,Knappt30procentfårensåpassavanceradbehandlingmedcellgifteroch/ellerstrålningattdetfinnsenteoretiskmöjlighetatttumörenkanförsvinna.Avdessahadeåttaprocentingenkvarvarandetumöridenbortopereradeändtarmenviddenefterföljandemikroskopiskaundersökningen.Avdepatienterdärtumörenförsvunnithelthade16procenttrotsdetenspridningavsjukdomentillregionalalymfkörtlar.Spridningtilldessalymfkörtlarinnebärenökadriskförspridningavsjukdomentillandraorgan.Detvisadesigocksåattdessapatienterhadesämreöverlevnadändepatientersomintehadenågonspridningtilllymfkörtlar,trotsattbådeändtarmmedlymfkörtlarvarbortopererade.Denfjärdestudienföljeruppresultatetavdentredje.Iochmedattantaletpatientermedcompleteresponseblirflersåharmaniandraländerbörjatavståfrånattopereradessapatienter.Dettaförattpatientenskaslippaenstoroperationmedstomisomföljdeftersomtumörenredantycksvaraborta.Detärrelativtenkeltattfastställaomtumörenitarmenförsvunnithelt,mendetärsvårareattmedmagnetröntgenskiljafriskalymfkörtlarfråndesomfåttspridningavtumörer.Dåvivetfråndenföregåendestudienattdetinteärheltovanligtmedspridningtilllymfkörtlarävenefteratttumörenförsvunnit,ochattdetdessutommedförsämreöverlevnad,ärdetviktigtattidentifieradepatientersomfåttensådanspridningtillkörtlarnainnandetfattasbeslutomattinteoperera.StudiengenomfördesisamarbetemedKarolinskaInstitutetiStockholm.Tvåerfarnaröntgenläkaremedstorkunskapiattbedömamagnetröntgenavdenhärtypenavpatienterfickbedömatidigaremagnetröntgenundersökningarfråntvågrupperavpatienter.Bådagruppernahadeändtarmscancerochsamtligahadefåttstrålbehandling,medellerutancellgiftsbehandlingsåatttumörenförsvunnitochdärefteropereratssåattoperationspreparatenkundeundersökas.Allapatienterhadeocksågenomgåttmagnetundersökningavbäckenetföreochefterstrål-/cellgiftsbehandlingen,meninnanoperationen.Hälftenavpatienternahadetumörkvarilymfkörtlarnamedandenandra

17

hälftenintehadedet.Röntgenläkarnasomgjordebedömningarnavissteintevilkapatientersomhadefriskalymfkörtlarochvilkasomintehadedet.Närvisammanställderesultatetvisadedetsigattmanintemedtillräckligstorsäkerhetvaresigkundebekräftaelleruteslutatumörilymfkörtlarnamedmagnetröntgenundersökning.BedömningavdenstörstalymfkörtelnsstorlekhosvarjepatientvisadesigkunnavaraettsättattidentifieradepatientersomhadeenspridningavtumörertilllymfkörtlarSlutsatsenblevattmagnetröntgenundersökninginteensamtkananvändasförattbedömaomkörtelnärfriskellersjukpådessapatienter,menattstorlekenpådenstörstakörtelnskullekunnaanvändasförattpåvisamisstankeomattpatientenharfåttenspridningavsjukdomentilllymfkörteln

18

19

Introduction.Colorectalcancerisanage-dependentmalignancythatisthesecondmostcommoncauseofcancer-relateddeathintheWesternworldandthesecondmostcommoncancerinwomenandmeninSweden.TheincidenceisalmostequalinmenandwomeninandisfairlystablethoughthereisaslightincreaseduetotheincreaseinaverageageinSweden.Rectalcanceraccountsforapproximately30%ofallcolorectalmalignancies(1,2).Theintroductionofpreoperativeradiotherapy(RT)inthetreatmentofrectalcancerhasreducedthefrequencyoflocalrecurrence,andRTisnowapartofthestandardtreatmentregimeforadvancedrectalcancer.Radiotherapyisoftencombinedwithchemotherapy,chemoradiotherapy(CRT).CRTinducesdownsizinganddownstagingofthetumourandregionallymphnodestherebyenablingsurgeryofanotherwiseinoperabletumour(1,3,4).Therearewell-knownshort-termandlong-termside-effectsofpelvicradiationandchemotherapy.FurthermorestudieshaveestablishedthattheresponsetoRTishighlyindividualandthatthismaypartlybeexplainedatthemolecularlevel(5-8).Inordertoavoidunnecessarysideeffectsitisimportanttodiscoverbiologicalfactorsthatcouldinfluencerecurrenceandsurvival,andtoidentifypatientsthatwillprobablynotbenefitfromRT/CRT.Anumberofclinicallyavailablebiomarkershavebeeninvestigatedastotheirabilitytopredictradiosensitivity,butsofarnonehascomeintoclinicaluse.Someareregardedaspromising.Examplesofsuchbiomarkersareepidermalgrowthfactor,(EGFR)thymidylatesynthase,p21andcarcinoembryonicantigen (CEA)(8-10).Adependablepredictorforneoadjuvanttreatmentresponsewouldspareprobablenon-respondersunnecessarysideeffectsandreduceunduetimewaitingforsurgery.Identificationofpotentialresponderswouldenablemoretailoredneoadjuvanttreatmentandindividualfollowupprogrammes.Inpatientswithanoutstandingresponsetoneoadjuvanttreatmenttheentireluminaltumourmayhavedisappearedpriortosurgery,aso-calledcompleteresponse,(ypT0N0M0).Extendedtimesbetweenchemoradiotherapyandsurgery,novelchemotherapeuticagentsandchangeinindicationsforneoadjuvanttreatmenthasledtoanincreaseinthefrequencyofcompleteresponse(11-15).Completeresponsecanoccurasaresultofstandardtreatmentfollowingnationalguidelinesforpreoperativedownstaging.Itcouldalsobeviewedasapreferredoutcomeinagoaldirectedtreatmentaimingtoavoidsurgery.Hencetheindicationsforneoadjuvanttreatmentcanbeextendedtoincludelessadvancedtumoursaswell(11).Therateofcompleteresponsevarieswiththeindication,asthereisabetterchanceofcompleteresponseinthelessadvancedtumours(11,16).Somesingleinstitutioncentershavepresentedhighcompleteresponseratesinsmalltumoursandinahighlyselectedpatientpopulation(12).Thereisaneedtoknowthefrequencyofcompleteresponseinalargeunselectedcohortfollowingnationalguidelineswherefactorsinfluencingincidenceandoutcomemaybeanalyzed.Whenconsideringaconservativewait-and-watchstrategyinpatientswithcompleteresponseboththesurgeonandthepatientneedtoknowtheindividualriskfactorsforrecurrentdiseaseandthelimitationsoftheimagingtechniquesusedforstagingandfollowup(17).Stagingandrestagingisofgreatimportancewhendecidingonneoadjuvanttreatmentandnon-surgicalmanagement.Asyettherearenoimplementedguidelinesforfollow-upafternon-surgicalmanagement.Highlyfrequentfollow-upsfor

20

manyyearsincludingphysicalexamination,endoscopy,CT-scansandMRIarenecessary(17,18)Figure1.MRIandendoscopicimagesofrectaltumoursbeforeandafterCRT,withluminalcompleteresponseinthesamepatient.

A. SagittalMRT2imageofrectalcancer(markedT).B. EndoscopicviewofthetumourinsamepatientC. PostCRTMRT2imagefromthesamepatientwithnovisibletumour,(arrow).D. PostCRTendoscopicviewshowingonlytelangiectasiaattheformertumoursite

(arrow).

21

Themolecularbackgroundtocolorectalcancer.Wedonotknowanysingleetiologyofcolorectalcanceroranyendogenousorexogenouscausativecarcinogensresponsibleforthedevelopmentofcolorectalcancer.Everyhumanisbuiltofapproximately60billioncellsthatareconstantlydividing.WitheverycelldivisionthereisariskforerrorintheDNAreplicationthatmaybeinheritedandmultiplied.Thelongerwelivethegreaterthenumberofmitosesthathaveoccurred,aswellasthegreatertheexposuretoenvironmentalcarcinogenssuchasradiation,chemicalsanddrugs.Veryeffectivecellularsystemexistsinthebodythatrepairorterminatemutationsinacellthatcouldotherwisebereplicatedandpassedontodaughtercells.Thissystemofrepairishowevernotfoolproof,andsomemutationsarenotcorrected.Thesemutationstogetherwithaccumulatedoncogeniceventseventuallyleadtothedevelopmentofcancer(19).In1990FearonandVogelsteinproposedtheadenomatocarcinomasequenceasamodelwithsuccessivegeneticmutationsleadingtocolorectalcancer.Thismodeldescribesthestepwisetransitionfromnormalepitheliumtocancerthroughmultiplemutationsinoncogenicandtumoursuppressorgenes(20)(Figure2and3).Figure2.Theadenoma-carcinomasequence.(ModifiedfromFearon-Vogelstein(20))

Normalepithelium

Earlyadenoma

Dysplasticadenoma

Carcinoma

Metastases

APC,COX2

Ki-RAS,DCC,SMAD4

p53

ECMdegradation

22

Despitealmost25yearsofresearchintothedevelopmentofcancer,theVogelsteinmodel,withsomeimportantmodificationsstillstandsastheacceptedmodelforcolorectalcancerdevelopment,thoughthereareothermodels,suchasthetheoryofcellfusion(21,22).Weknowthatmanymutationstakeplaceinthevariousstepstowardsinvasivecancer,andthegreaterthenumberofmutationsoccurringthegreatertheriskforcancer.Furthermore,thecumulativenumberofmutationsismoreimportantthanthesequentialorder(20)(Figure2)Figure3.Commononcogenesincolorectalcancer.

Oncogenesincolorectalcancer

Protooncogenes

K-ras(Kirsten-ratsarcoma)

Supressorgenes

APC(AdenomatousPolyposisColi)

p53(Protein53kDaDCC(DeletedinColorectalCarcinoma)DNAmismatchrepairgenes.(Resposibleinhereditarynonpolyposiscoloncancer(HNPCC))hMSH2hMLH1hPMS1hPMS2

Thecolonandrectumareformedof107glandularcryptseachwiththousandsofdifferentiatedcellsofpolyclonaloriginandasmallnumberofstemcells(lessthan10percrypt).Thesestemcellsareprotectedfromthehostileintestinalenvironmentatthebottomofthecrypts.Thedifferentiatedcellsdividerapidlyandmigratetothetopofthecryptwhere1010cellsareshedeachday(19).Proliferationislimitedtothelowertwothirdsofthecryptsandthematurecellsareshedatthesurface.ThefirststepinthemonoclonalmalignanttransformationiscausedbyindividualmutationstobothallelesofthetumoursuppressorAdenomatousPolyposisColi(APC)gene.Thisinitialmutationshiftscellproliferationtotheupperportionofthecryptwherethedividingcellsaremoreexposedtothehazardouscontentsofthebowel.TheAPCgeneisarestrainerofproliferationandthelackofthisfunctionleadstouncontrolledcellgrowthandtheformationofapolyp(20).OverexpressionofCOX1andCOX2cyclooxygenases,catalyzesthearachidonicacidderivatemalondialdehydewhichitselfismutagenicandintensifiesthemalignantprocessbypromotingcellmigrationandproductionofangiogenicstimulatoryfactors(23).Thisisthoughttooccurafterthemutationofthesecondalleleofthegene.TheseinitialstepsofmalignanttransformationarereversibleasseenafteradministrationofNSAID,wherethereisareductioninbothsizeandnumberofpolypsthroughCOX2inhibition,thisledtotheconceptofCOX2inhibitorsinprophylaxisortreatmentofcolonadenomas(24).

23

FurthermutationsareneededtotransformtheadenomatoinvasivecancerandamutationoftheKi-rasproto-oncogeneincreasescelldivisionandleadstoincreaseddysplasiaintheadenoma.MutatedKi-rasisnotexpressedinearlybenignadenomasbutincreasesinexpressionindysplasticpolypsandcancersandisthusimportantformalignanttransformationinmany,butnotallcolorectalcancers(25).MutationsintheDeletedinColorectalCarcinoma(DCC)geneandSMAD4gene,bothofwhichplayaroleincelladhesionandstromalproliferation(20,26)arealsoimportantsteps.Oneofthefinalstepsonthepathtomalignancyisthemutationofbothalleles(doublehit)ofthetumoursuppressorgenep53.Thep53isknownasthe“guardianofthegenome”byrecognizingDNAdamageandinducingG1cellcyclearrestduringDNAreparationor,inthecaseofirreparabledamages,initiatingapoptosis(27).Mutationsofthep53genearefoundinin75%ofallcolorectalcancercellsbutarerareinadenomas(28).Mutationofp53resultsinreducedp21transcription,cumulativeDNAdamageanduncontrolledprematurereplicationofp53seemstohaveamoderateeffectinnormalcellsbuthasagreatereffectincellsstressedbyradiationorcytotoxicdrugs(29).

DNAMismatchRepairgenes(MMR)areresponsiblefortherepairofmismatchesinbasepairs.CellswithabnormallyfunctioningMMRareunabletocorrecterrorsthatoccurduringDNAreplicationandconsequentlyDNAerrorsaccumulate.Thisleadstothecreationofnovelmicrosatellitefragments.MicrosatellitesarecomposedofrepeatedDNAsequences.Thesesequencescanbemadeupofrepeatingunitsofonetosixbasepairsinlength.Mutationofthegenewillresultindefectiverepair,microsatelliteinstabilityandanincreaseindysplasia,bothofwhichareseenin13%ofsporadiccolorectalcarcinomasandinallHNPCC(30).

Theabilitytometastasizeistheleastunderstoodstageinthestepwiseprogressiontheory.Forcellstobeabletometastasizethecell-celladhesionsmustbedisrupted.ReductionincelladhesionsispartlyduereducedexpressionofEcadherin(31).VariousmetalloproteasestakepartinaproteolyticcascadethatdegradesECMcomponentsanddisruptsextracellularmatrix(ECM)cellinteraction(32).Intravasationofmalignantcellsintothebloodstreamandresistancetothemajorhistocompabilitycomplexsystem,whichremovescirculatingtumourcells,ispoorlyunderstood.Animalstudieshavedemonstratedthatonlyasmallportionofthemalignantcellsenteringthebloodstreamhavetheabilitytoestablishmetastasesbyavoidingbeingkilledbycirculatingimmunecellsorbyestablishingacolonyatadistantsite.Carcinoembryonicantigenthatisusedasatumourmarkerincolorectalcancerisbelievedtoplayaroleinthisprocessaswellasendothelialgrowthfactorthatisatargetfornovelcytotoxicdrugs(33,34).

24

25

Radiationtherapy.Theeffectsofradiationtherapymaybedividedintothreeseparatephases.ThephysicalphaseThephysicalphaseisshortandbasedontheinteractionsofchargedparticleswiththetissueDNA.Ittakesanelectron10-18secondstopassthroughtheDNAmoleculeandthejourneythroughtheentirecelltakesaround10-14s.Duringthisshorttimetheelectronorphotonwillinteractandejectelectronsfromatoms(ionization).Theseejectedelectronsmayionizenearbyatomsgivingrisetoanionizationcascade.ForeveryGrayofabsorbedradiation105ionizationstakeplaceforevery10µmoftissuepenetrated.ThechemicalphaseThechemicalphaseisthetimeperiodwhendamagedatomsreactwithcellularcomponents,breakingchemicalbondsandformingsplitmolecules,i.e.freeradicals.Duringthistimespanof1ms,protectivescavengersreactionsincludingsulphydrylcompounds,chemicallyinactivatethesefreeradicals.ThebiologicalphaseThisphaseincludesallotherprocessesthatfollow.MostdamagedDNAissuccessfullyrepaired.However,cancercellswithmutationsingenes,suchasp53arerapidlydividingandhaveadefectDNArepairsystemcausingincreasedcelldeathcomparedtonormaltissueafterradiation.Whenthemutationsleadtocelldeath,aprocessthattakestime,acellmayundergomanydivisionsbeforeitdies.Theearlyeffectsofradiationonskin,mucosaorbloodcomponentsareduetothekillingofstemcells.ThelateeffectsofradiationtherapysuchassecondarytumoursarealsoduetotheinitialDNAdamage(35).Radiationtherapyisusedasneoadjuvanttreatmentforrectalcancereitheraloneorincombinationwithchemotherapy.Twodifferentregimensexists,Short-termRadiotherapy(SRTe.g.5x5Gy)isdeliveredoverfivedaysfollowedbysurgerywithinfivedays.TheindicationisusuallyT3btumoursinthemiddleandlowerrectumaswellasmesorectalN+tumoursprovidedtheCRMisclear.SRThasnodownstagingeffectasthetimebetweenradiationandsurgeryistooshort.Itisusedtosterilizethepelviclymphnodesinordertoreducelocalrecurrencei.e.withinthepelvis(1).HoweversurgerymaybepostponedforseveralreasonstherebyincreasingthechancethatSRTalsohasadown-stagingeffect.Thisistermed“SRTwithdelay”whichisusuallydefinedasadelayofmorethanfourweeksbetweenradiotherapyandsurgery.LongTermRadiotherapy(LRT(e.g.28x1.8-2Gy),hasanintervalof6-8weeksbeforesurgeryandcanleadtosterilizationanddownstagingofboththetumourandadjacentlymphnodesandisindicatedforadvancedT3andT4tumours.Thereareseveralshort-andlong-termsideeffectsofpelvicradiationsuchasurinaryandfecalincontinence,sexualdysfunction,peripheralnervedamageandpathologicalfractures.Smallboweltoxicitywithanincreasedriskforbowelobstructionisprobablythemostfrequentsideeffect(5,36,37).Theincidenceofsevereradiotoxicitywithleukopenia,abdominalpainanddiarrheaisaround5%(38,39).ThelateeffectsofRTmayaddtothecomplicationsofpelvicsurgery.Bothirradiationandthesurgicaltraumainthevicinityofpelvicnervescanharmthenervescontrollingsexualfunctionandcontinenceofboththebowelandbladder.

26

TheincreasedriskfornervedamageafterRT,independentofsurgicaltrauma,hasbeendescribedinseveralstudies(5,36).Theriskforsecondarycancerisincreasedafterirradiation(36)SeveralstudieshavedemonstratedthatLRTandSRTwithdelayhavecomparabledownstagingeffectandreductionintherateoflocalrecurrence(38-40).Thereisacleardose-responsebetweentheRT-doseandthetumourdownstagingwhenthesamefractionationsarecompared(35,41).WithtailoredextendeddelaysbetweenCRTandsurgery,anincreaseinthefrequencyofcompletepathologicalresponse,(ypT0N0M0)isevident(11-15).

27

NeoadjuvantchemotherapyThefluoropyrimidines(5-fluorouracilandfluorodeoxyuridine),whengivenincombinationwithradiationincreasetheeffectivenessofneoadjuvanttreatment.IncreasedradiationsensitivityoccursincellsthatprogressinappropriatelyintotheSphaseduetoDNAdamageinflictedbyradiation.Thiscouldprovidethemolecularbasisfortheselectivekillingoftumourcellsratherthannormaltissuecells(42).FluoropyrimidinebasedchemotherapycanbeusedinconjunctionwithbothLRTandSRT,inthemostadvancedformsofrectalcancer(chemoradiotherapy,CRT),actingasaradio-sensitizertoincreasetheeffectofradiotherapy(43).CRTincreasestherateofcompleteresponsecomparedtoradiotherapyalone(40).Cisplatin,aplatinumbasedchemotherapy,hasmultipleeffectsoncells,oneofthembeingDNAdamagerepairinhibitionbuttheexactmechanismisnotknown(42).Theadditionofoxaliplatin,anotherplatinum-basedchemotherapyagent,to5-FUforadjuvanttreatment(44),reducestheriskforrecurrenceby25%inrectalcancer.Intheneoadjuvantsetting,oxaliplatinhasnotbeenshowntobeabetterradiosensitizer.Otherchemotherapeuticagentssuchasirinotecanormonoclonalantibodiessuchasbevacizumabhavenotbeenshowntohavethiseffecteither(45).Theside-effectsof5-FUbasedchemotherapyassingletherapyorincombinationwithothertherapiesintheneoadjuvantsettingareusuallywelltoleratedwithlessthan5%havingseveretoxicreactionsbecauseoftheshort-termexposure(46).Currenttreatmentschedulesincludenearly6weeksofneoadjuvantchemoradiation,6-8weeksofrecoverypriortosurgery,andanother4weeksofrecoverypriortoconsiderationforadjuvanttherapy.Inthiswaythereisaminimum4monthsdelaybeforeinitiationoffulldosesystemictherapy,(seeflowchartfollowingpage).Startingfulldosechemotherapyatanearlierstagehastheadvantageoftreatingmicro-metastaticdiseaseearlier,therebyreducingtheincidenceofdistantrecurrence.Furthermoreinmoststudiesradiotherapyhasnotimprovedsurvivalbutprimarilyreducedlocalrecurrence(1).Thusanalternativecouldbeneoadjuvantchemotherapyalone.Thereislimitedexperienceofchemotherapyassingletreatmentmodalitybutinitialreportsareencouragingintermsofbothdown-stagingandoutcomebutfurtherresearchwithlong-termfollow-upisneededandinitiated(43,46,47).

28

Figure4.ExampleofatheoreticalflowchartwithtreatmentoptionsforaSwedishpatientwithrectalcancer2016.

29

Surgicaltreatment.JacqueLisfrancperformedthefirstformalperinealresektionforrectalcancerin1826.GaussenbauerandHartmann1879addressedtheproblemwithlimitedexposurebyperformingresectionsviaanabdominalapproach(48).ErnestMilesstudiedthelymphaticspreadanddemonstratedanupwarddirectionoflymphflow.Between1899and1906heperformed57perinealresectionsofwhich95%developedearlyrecurrence.Inthepostmortemhefoundrecurrenceintheperitoneumandinlymphnodesaroundtheleftiliacartery.Hestated,“Ihavefailedinoneimportantaspect-namelythecompleteeradicationofthezoneofupwardspread”(48).In1907heperformedthefirstabdominoperinealresectionenablingresectionoftheupwardspreadtolymphnodes,theMiles´Operation(49).In1923hehadarecurrencerateof29.5%,whichwasoutstandingcomparedtopreviousresults(50).TheMiles´procedurebecamethegoldstandardandwasimprovedbyLloyd-Davisasaone-stageoperationincontrasttoMiles´two-stageprocedure.Moynihanadvocatedforthehightieoftheinferiormesentericarterysoastoincludelymphnodesthatcouldbeafuturelocusformetastaticgrowth,acontroversythatisnotyetsolved(51). In1948ClaudeDixonpresentedtheresultsof400patientsoperatedwithanteriorresectionformiddleandupperthirdrectalcancermaintainingbowelcontinuityinsteadofthepermanentstomausedintheMiles’operation(52).In1982HealddescribedthelymphaticspreadwithinthemesorectalsleeveandformulatedtheconceptofTotalMesorectalExcision(TME)withenblocresectionoftherectumandmesorectumandsharpdissectioninwelldefinedplanesasopposedtobluntmanualextractionusedpreviously.Inanarticlefrom1986hereportedon115patientswhereonly3localrecurrenceshadbeenseenafterafour-yearfollowup(53,54).TheTMEconceptrevolutionizedrectalcancersurgeryandisnowthegoldstandardworldwide.Anteriorresection.Anteriorresection(AR)isthemostcommonsurgicalprocedureforrectalcancerbeing40%ofthesurgicalproceduresforrectalcancerinSweden2015(2).Theprocedureisdecreasinginpopularityprobablyduetoagreaterawarenessamongstsurgeonsandpatientsofpoorpostoperativebowelfunctionwithaverylowanastomosisandthefearofcomplications.Theoperationincludesresectionoftherectum,mobilizationoftheleftcolon,anddivisionoftheinferiormesentericartery.Theleftcolicflexureisusuallytakendowntoallowatension-freeanastomosis.Therectumismobilizedcircumferentiallytothepelvicfloor,or5cmdistaltothetumouraccordingtotheTMEtechnique.Thedescendingcolonandthedistalendofrectumisdividedandacolorectalanastomosesiscreatedusingacircularstaplingdevice.Divertingileostomyisindicatedwithalowrectalanastomosis(2).Theprocedurecarriesa10-15%riskforanastomoticleakageleadingtopelvicabscessandsepticemia.Thereisariskfordamagingthenervescontrollingbladder,analsphincterandsexualfunction,ariskthatisalsoincreasedbypreoperativeradiation.Theoperationisasphincter–sparingprocedureifthedivertingstomaisreversed.RecentlytheLowAnteriorResectionSyndrome(LARS)withincontinence,urgency,andfrequentbowelmovementshasbeenhighlightedandhasbeenshowntocauseconsiderablefunctionallong-termbowelfunctionproblemsaftersurgery(55).

30

AbdominoperinealResectionAnabdominoperinealresection(APR)isindicatedforthemostdistaltumours.TheabdominalpartoftheoperationisperformedasinanAR.Thesecondpartoftheoperationisperformedwithaperinealapproach.Theanus,analcanalandpartsofthepelvicfloorareincludedintheresection.Thepatientisleftwithapermanentcolostomy.In2015,25%oftherectalcanceroperationsinSweden,wereAPR(2). Hartmann’sResection.InaHartmann’sresectionthesameabdominalprocedureasinARisperformed,butastheindicationsforthisprocedureareconcernsaboutanastomoticcomplicationsinoldage,poorhealthorexpectedpostoperativefunctionalproblems,noanastomosisisconstructed.Thepatientisleftwithacolostomyandtheclosedrectalstumpisleftinsitu.Hartmann’sresectionsisperformedinlessthan10%oftheabdominalresections(2).LocalExcisionandTransanalEndoscopicMicrosurgery(TEM).TheseoperationsareindicatedforT1cancersorasapalliativeprocedureinpatientsunfitforabdominalresection.TEMusesalargeendoscopeencompassinginstrumentsfordissectionandgasinsufflation.Full-thicknessresectionsmaybeobtainedandtheboweldefectisclosedorleftopenforsecondaryhealing.Themajordisadvantageofthistechniqueisthatevenifthetumourisradicallyresected,theregionallymphnodesareleftinsituandcannotbeexaminedpathologically.Minimallyinvasivetechniquessuchaslaparoscopicandroboticsurgeryhaveimprovedvisualizationandfurtherreducedtheperioperativetraumastillwithoutimprovedoncologicaloutcome(56,57).

31

Magneticresonanceimaginginrectalcancer.High-resolutionT2-weightedimagingisthekeysequenceinthemagneticresonance(MR)imagingevaluationofrectalcancerbothfortheprimarystagingandinrestagingafterchemoradiotherapy.Thetechniquecan,withhighaccuracydifferentiatebetweenrectaltumoursconfinedtotherectalwall(StageT2)fromthosethatextendbeyondthemuscularispropria(StageT3)(58,59).Severalstudieshaveshownthathigh-resolutionMRimagingisareliableandreproducibletechniquewithhighspecificityforassessingthedistanceofthetumourfromtheCRM(60).However,assessmentofnodalinvolvementremainsproblem.Priortostartingneoadjuvanttreatment,thesizeandmorphologyofnodesmaytoacertaindegreebeusedtodiscriminatebetweenbenignandmalignantlymphnodes.However,afterCRTtreatmentmorphologyisnolongerareliablecriterionandsizealonehassignificantlimitations.Assessmentofnodalstageseemstobehighlydependentupontheexperienceoftheradiologist(61-63).Diffusionweightedimaging(DWI)isanMRItechniquethatquantifiesthemovementofwatermoleculesatthecellularlevel.Sincethepropertiesofwatervaryinareasofnecrosis,inflammationandfibrosis,theDWItechniqueimprovesthestagingofcancerandfacilitateslymphnodedetection.ThereisnoconsensusontheuseofDWIinrectalcancerstaging,anditisnotreliablefordifferentiatingbetweenbenignandmalignantlymphnodes(64,65).

32

MRimagingofthepelviswithrectalcancer.A. SagittalT2viewofalargerectalcancer.B. TransverseT2viewofcircumferentialrectalcancer.C. TransverseT2viewwithalaterallymphnodeindicatedwitharrow.

A

B

C

33

Aimsofthethesis

Theaimsofthethesiswere;- toinvestigatetheexpressionofFXYD-3inrectalcancerandthe

relationshipofFXYD-3expressiontosurvivalinpatientswithorwithoutpreoperativeradiotherapy:

- toinvestigatethepotentialroleofFXYD-3asabiomarkerfordecreasedradio-sensitivity,usinglocalrecurrenceofrectalcancerasaproxy:

- toinvestigateinaprospectivenationalregister-basedstudytheimpactofneoadjuvanttherapyontheincidenceandoutcomeofpathologicallyconfirmedcompleteresponse:

- toassesstheaccuracyofMRIinpredictingthepresenceofremainingmesorectallymphnodemetastases(ypT0N+)inpatientswithcompletepathologicallyconfirmedluminalresponse(ypT0)afterneoadjuvantradiotherapyorchemo-radiotherapy.

34

35

PatientsandMethodsStudyIInstudyI,140specimensfrompatientsthatparticipatedinaSwedishrandomizedtrialonpreoperativeradiotherapy(RT)between1987and1990wereanalyzed.Allpatientshadprimaryrectalcarcinomaand65ofthe140received5x5GyRToverafive-dayperiod,followedbysurgerywithinaweek.Noneofthepatientshadadjuvantchemotherapyandthemeanfollow-uptimewas84months(66)(Table1).PatientswereanalyzedforexpressionofFXYD-3intheprimarytumour,normalmucosaandregionallymphnodemetastases.Immunohistochemicalanalysiswasperformedonparaffin-fixedsectionsusingamonoclonalanti-FXYD-3primaryantibody(Fig.1)Degreeofstainingwasgradedasnegative,weak,moderateorstrongbasedontheintensityofthestaining.Thestainedsectionsweremicroscopicallyexaminedandscoredindependentlybytwoinvestigatorsblindedtotheclinical,pathologicalandbiologicdata.Statistics.McNamara’smethodandChi-squarewereusedtotestthesignificanceofdifferencesinFXYD-3expressionbetweendistantnormalmucosa,adjacentnormalmucosa,theprimarytumourandlymphnodemetastases,andtheassociationofFXYD-3expressionwithclinical,pathologicandbiologicvariables.TherelationshipbetweenFXFD-3expressionandsurvivalwastestedusingCox’sproportionalhazardsmodel.SurvivalcurveswerecalculatedusingtheKaplan-Meiermethod.Alltestsweretwo-sidedandap-valueoflessthan0.05wasconsideredasstatisticallysignificant.Figure1.ImmunohistochemicalstainingforFXYD-3expressionfromthesamepatient.A:weakexpressionindistantnormalmucosa.B:Strongexpressioninprimarytumour,C:weakexpressioninlymphnodemetastases.

36

Table1.Characteristicsofpatientsandrectalcancers

Table1.Characteristicsofpatientsandrectalcancers

Characteristics Non-Radiotherapy Radiotherapy No. % No. %Gender

Male 44 59 41 63Female 31 41 24 37

Age(years) ≤67 31 41 28 43>67 44 59 37 57

TNMstage I 20 27 21 32II 19 25 20 31III 54 41 17 26IV 5 7 7 11

Differentiation Well 5 7 5 8Moderately 53 71 40 62Poorly 17 23 20 31

Numbersoftumors Single 63 84 48 74Multiple* 10 13 16 25Unknown 2 3 1 2

Surgicaltype Rectalamputation 37 49 25 38Anteriorresection 38 51 40 62

Resectionmargin Tumourfree 73 97 60 92Tumourinvolvedmargin 2 3 5 8

Distancetoanalverge(cm) Mean 7.6 8.6

*Othercolorectalcancerorothertypeoftumourbesidesthepresentrectalcancer.

37

StudyIIDataonpatientswithrectalcancerfromthreehealthcareregionsduringthetimeperiod1985-2000wereextractedfromadatabase.Allpatientshadbeenoperatedforrectalcancer.ThemajorityofpatientsreceivingRTreceived5x5Gyfollowedbysurgerywithinaweek.Patientswithlocallyadvanceddiseasereceived25x1.8Gyandsurgeryafter6-8weeks.1180patientswereincludedandoperatedonwithradicalresection(R0)usingtheTMEtechnique(67,68).Forty-eightpatientswerediagnosedwithalocalrecurrence(LR)oftherectalcancerwithinthepelvis.Patientswithliverorlungmetastaseswerealsoincluded.Anestedcase-controlstudywasdesignedwithtwocontrolpatientsforeveryLRcase.ControlsandcaseswerematchedforgenderandpreoperativeRT(Table1).Themediantimeforfollow-upforthecasegroupwas79weeksandforthecontrolgroup316weeks.Wewereabletoretrieveformalin-fixedblocksfromtheprimarytumourof48casesand81controls.FXYD-3expressionwasanalyzedusingimmunohistochemistryontumortissuefromtheindexrectalcanceroperation.Theintensityofstainingwasgradedasnegative,weak,moderateorstrongbasedontheintensityofthestaining.Thecaseswithnegative,weakandmoderateintensityweregroupedtogetherastheweakFXYD-3expressiongroupandthecaseswithstrongintensityformedthestrongFXYD-3expressiongroup.ThestainingandexaminationprocesseswereperformedattheKarolinskaInstitute,Solnabytwohisto-pathologistsblindedforclinic-pathologicandbiologicdata.Statistics.TheChi-squaremethodwasusedtotestthesignificanceofthedifferencesinFXYD-3expressionbetweenthestrongFXYD-3expressiongroupandtheweakFXYD-3expressiongroup.ThefiguredepictingtimetolocalrecurrencewascalculatedusingtheKaplan-Meiermethod.Alltestsweretwo-sided,andavalueofp<0.05wasconsideredstatisticallysignificant.LogisticregressionandCoxregressionwereusedtoanalyzetheeffectofdifferencesbetweenthecasegroupandthecontrolgroup.Figure1ImmunohistochemistryshowingFXYD-3expressionintheprimarytumourfromdifferentpatients.AWeakFXYD-3expression.BStrongFXYD-3expression

38

Table1PatientcharacteristicsattheindexoperationandFXYD-3expressionCharacteristics Local

recurrenceGroup

ControlgroupP-valueP-value(Unadjusted)(Adjusted)*

Patientsn,(%) 48 81Timetorecurrence(mo)

median 18 ---Range 3-60

Age(y) Median 71 720.36-Range 34-85 34-95--

Gender(n) Male 24(50) 45(56)0.540.96Female 24(50) 36(44)--

Typeofsurgery(n) Anteriorresection 32(67) 65(80)0.080.88Abdominoperinealresection

16(33) 16(20)--

Distanceofprimarytumorfromanalverge(n)

11-15cm 15(31) 28(35)0.710.486-10cm 16(33) 31(38)--0-5cm 17(35) 22(27)--

Radiotherapy(n) Yes 18(38) 25(31)0.440.97No 30(62) 56(69)--

TNMstage(n) I 4(8) 26(32)0.010.02II 19(40) 36(44)--III 25(52) 19(23)--

Tumourdifferentiation

High 3(6) 6(8)-0.03Moderate 30(64) 61(81)--Poor 14(30) 8(11)--

FXYD-3Expression Weak(Grade0+1+2)

39(81%) 67(83%)

Strong(Grade3) 9(19%) 14(17%)p>0.05*Adjustedforallothervariablesinthetable

39

StudyIII.StudyIIIisaregister-basedstudyontheincidenceandoutcomeofcompletepathologicalresponseofrectalcancertoneoadjuvanttreatmentinSwedenbetween2007and2012.TheSwedishColo-RectalCancerRegister(SCRCR)isaprospectivepopulation-basedregistercollectingdatafromallcolorectalcancercasesinSweden(69).Thisisavalidatedregisterwith99.5%immediatecoverageandfive-yearfollow-updatafrom98%ofpatients.Thestudycohortconsistedof11226patientswithamedianageof71years59%weremales.Anabdominalprocedurewasperformedon7885ofthepatients.Twenty-sixpercent(2063patients)wereclassifiedashavingpotentialforpCRafterreceivinglong-termradiotherapytreatment(28x1.8Gy,LRT)orshort-termradiotherapytreatment(5x5Gy,SRT)withadelayofmorethanfourweeks,withorwithoutchemotherapybeforeabdominalsurgery.Thisgroupwaslabeled“potentialcompleteresponders”andformedthebasisofthisstudy(Table1).Amajorityofthe2063potentialresponders(84%)werecT3orcT4cancers,and56%hadreceivedneoadjuvantchemotherapy.PatientswithypT0wereidentifiedfromthatgroup.Thegroupof161patients(8%)withcompleteresponsewasfurtheranalyzedforlymphnodestatusandduringthatprocesserrorsandmisclassificationsintheregisterwerediscoveredandcorrected.

Statistics.Differencesbetweentheproportionsofgroupsweretestedwithatwo-sidedZ-testofproportion.Thenon-parametricMann-Whitneyu-testwasappliedfordifferencesbetweenmediantimes.OverallsurvivalwaspresentedasaKaplan-Meiercurve,anddifferencesinsurvivalweretestedwithGehan’sgeneralizedWilcoxontest.Five-yearsurvivalrateswerecalculatedusinglifetables.RelativerisksformortalitywerecomparedusinghazardratioscalculatedwithCOXregression.Binomiallogisticregressionwasimplementedtogetoddsratios.Table 1. Patient characteristics

Female M1*

Rectal cancer (2007-2012) n - % 11226 41% 20%

age (median)

71 71

Abdominally operated ** n - % 7885 40% 8%

age (median)

69 69

Anterior resection n - % 3940 42% 12%

age (median)

67 66

Abdominoperineal resection n - % 2837 38% 11%

age (median)

70 70

Hartmann's procedure n - % 1108 42% 8%

age (median)

78 77

Potential complete responders (Long-term RT or short-term RT with delay, +/- chemotherapy.)

n - % 2063 40% 13%

age (median)

66 67

Long-term radiation. n - % 1179 41% 10%

age (median)

64 64

Short-term radiation with delay. n - % 884 38% 16%

age (median)

71 73

*10oftheypTOpatientshaddistantmetastases(M1).*368patientswithrectalcancerhadalocalexcisionofthetumourandwerenotincludedinthiscohort

40

41

Study IV.

StudyIVwasafollow-upofthefindingsofstudyIIIonremainingloco-regionallymphnodemetastasesinluminalcompleteresponseandthefollowingreducedsurvival.TheSCRCRwasscrutinizedandfrom11226patientswithrectalcancerdiagnosedbetween2007and2012agroupof161patientswithluminalcompleteresponse(ypT0Nall)wereidentified.Fromthatgroup26patientswithypT0N+wereselectedinordertostudytheaccuracyofMRIindetectingremainingtumourpositivelymphnodes.WewereabletoretrievemedicalrecordsononcologicaltreatmentandcompleteMRIimagingfromthestagingandrestagingMRIinvestigationsfrom19patients.Another19patientswithypT0N0werematchedfortreatinghospitalandcomprisedthecontrolgroup(Table1).Allimageswereassessedbytworadiologistsblindedtosurgicalandpathologyfindingsfirstindependentlyandtheninconsensus.Imagesbeforeandafterneoadjuvanttreatmentwereassessedtogether. Extramuraldepthoftumourinvasionandinvolvementofthemesorectalfasciawerenotedaccordingtopreviouslyestablishedcriteria(60).Nodalnumber,sizeandpositionwereidentifiedineachpatientforbothbenignandtumourpositivelymphnodes.ThelymphnodesidentifiedonMRIwerejudgedtobemalignantorbenignusingmorphologiccriteria(62,70).Onthepre-treatmentMRIalymphnodewasconsideredtobemalignantifitshowedanirregularouterborderorinternalsignalheterogeneity.OnthepostCRTMRI,sizewasusedastheonlycriterion,wherelymphnodesexceeding5mmwereregardedasmalignant.Statistics

• Sensitivitymeasurestheproportionofpositivesthatarecorrectlyidentifiedassuch(e.g.thepercentageofsickpeoplewhoarecorrectlyidentifiedashavingthecondition).

• Specificitymeasurestheproportionofnegativesthatarecorrectlyidentifiedassuch(e.g.,thepercentageofhealthypeoplewhoarecorrectlyidentifiedasnothavingthecondition).

• Positivepredictivevalue=probabilityofdiseaseamongpatientswithapositivetest

• Negativepredictivevalue=probabilityofnodiseaseamongpatientswithanegativetest

TheStudent´sT-testwasusedtotestthesignificanceofthedifferencesbetweenthecasesandthecontrolgroup.Alltestsweretwo-sided,andavalueofp<0.05wasconsideredstatisticallysignificant.Logisticregressionwasusedtoanalyzetheeffectofdifferencesbetweenthecasegroupandthecontrolgroup.

42

Table1.Descriptionofthestudypopulation.

.

Gender All N+ N0 pFemale 17 11 6 0.10Male 21 8 13 Averageageatsurgery(range).years 57(37-74) 54(37-69) 61(37-74) 0.05 T-stage 0.18T1-T2 9 5 4 T3 14 8 6 T4 14 5 9 Tx 1 1 Radiation 0.7328x2Gy 27 13 14 5x5Gywithdelay 11 6 5 Chemotherapy 0.18None 7 3 4 5-FU/Capecitabine 18 7 11 5-FU/Capecitabine+Oxaliplatiine 13 9 4 Sum 38 19 19

43

ResultsanddiscussionStudyITheexpressionofFXYD-3wassignificantlyincreasedintheprimarytumourcomparedtonormalmucosa(p=0.008)(Fig1).Therewasnodifferenceinexpressionbetweentheprimarytumourandtumourpositivelymphnodes.TherewasahigherFXYD-3expressioninmenthaninwomen(p=0.04)andintumourswithinfiltrativegrowthcomparedtotumourswithexpansivegrowth(p=0.02).FXYD-3expressionwaspositivelyrelatedtobothphosphataseofregeneratingliver(PRL)(p=0.001)andp73(p=0.03).InpatientsreceivingRT,FXYD-3expressionwasstrongerintumourswithlessnecrosisthanintumourswithextensivenecrosis(p=0.02).Inbothuni-andmultivariateanalysispatientswithstrongFXYD-3expressionalone(P=0.02)orincombinationwithPRL(p=0.02)hadreducedsurvivalintheRTgroup,regardlessoftumourstageordifferentiation(Fig2).Fig. 1. Strong FXYD-3 expression in the radiotherapy (RT) group and non-RT group in distant normal mucosa, adjacent normal mucosa, primary tumour and tumour positive lymph nodes.

FXYD-3 expression

3

4

15

0

3

4

15

10

0

2

4

6

8

10

12

14

16

Distant normal mucosa Adjecent normal mucosa Primary tumor Metastasis

% o

f cas

es w

ith s

trong

FXY

D-3

expr

essi

on

RTnon-RT

44

Figure2.Univariateanalysisofsurvivalvs.FXYD-3andPRLexpressionintheRTgroup

FXYD-3isatrans-membraneproteinnormallypresentinbodytissuesbutoverexpressedinseveralcancers.Increasedexpressioninearlytumourdifferentiationandtumourproliferationhasindicatedthatitcouldpossiblybeusedasatumourmarker(19,71-75).TherearealsoindicationsthatFXYD-3maybeinvolvedintumourresistanceto5-FUchemotherapy(76).AtthetimeofthestudynopreviousresearchhadanalyzedtheclinicalsignificanceofFXYD-3incolorectalcancer.OuraimwastodeterminewhethertherewasanincreasedexpressionofFXYD-3inrectalcancercomparedtonormalmucosa,andtoidentifydifferencesinoutcomebetweenpatientswithorwithoutRTandrelatethesetoFXYD-3expression.OurresultsshowedthattherewasincreasedFXYD-3expressionintheprimarytumourcomparedtonormalmucosa,andintumourswithinfiltrativegrowth.TheassociationofFXYD-3expressionwithp73andPRLisofinterestasinpreviousstudiesbothPRLandp73havebeenshowntoberelatedtoradio-sensitivity.Furthermore,overexpressionofp73isalsorelatedtoreducedsurvivalincolorectalcancer(6,77-79).LesstumournecrosisandpoorersurvivalwereseeninpatientswithincreasedFXYD-3expressionintheRTgroupbutnotinthegroupwithoutRT.Alowerdegreeoftumournecrosiscanbeseenasanindicatorofreducedradio-sensitivity.Therewasalsoanon-significantincreaseindistantmetastases(p=0.08)inthisgroup.TheseresultstakentogethersuggestedtousthatexpressionofFXYD-3couldbeaprognosticfactorandanindicatorofreducedradiosensitivity.SincethiswasthefirststudyonFXYD-3andcolorectaloutcome,ourfindingsrequiredconfirmation.Astudyonreducedradio-sensitivityusinglocalrecurrenceasaproxywasconsideredtobemoreaccuratesincefewstudieshavebeenabletoshowacorrelationbetweenRTandsurvival(1).WethereforewentontoattempttoconfirmthesignificanceofFXYD-3inrectalcancerbystudyingthefrequencyoflocalrecurrenceafterRT(studyII).

0 24 48 72 96 120 144 168 192

Follow-up time (months)

0,0

0,2

0,4

0,6

0,8

1,0Su

rviv

al p

roba

bilit

y

RT, n=57, P = .01

Both negative

FXYD3 and PRL expression

Either positive or both positive

RT, n=57, P = .01

B

45

StudyIITherewasnodifferenceinFXYD-3expressioninrelationtoRTneitherinthecontrolgroupnorinthelocalrecurrence(LR)group(p>0.05)(Table2).Therewasnosignificantdifferenceintimetodiagnosisofalocalrecurrence,betweentumourswithstrongFXYD-3expressionandthosewithweakFXYD-3expression(Figure1).Whenallpatientswereanalyzedtogether,i.e.boththosewithandwithoutLR,therewasnodifferenceinsurvivalintheradiatedgroupbetweenpatientswithstrongorweakFXYD-3expression(p=0.43).Therewasnodifferenceinsurvivalinthenon-radiatedgroupbetweenthepatientswithstrongorweakFXYD-3expression(p=0.30).TherewasatendencytowardsalowerincidenceofstrongFXYD-3expressioninpatientswithLRwhohadbeentreatedwithpreoperativeRT(Table3).Figure1.Timetolocalrecurrenceinall129patients.

p>0.05

Table1.FXYD-3Expressioninthecontrolgroupinrelationtopreoperativeradiotherapy(RT)(n=81)

p>0.05 Table2.FXYD-3expressioninthelocalrecurrencegroupinrelationtopreoperativeradiotherapy(RT)(n=48)

p>0.05

0 20 40 60

Time after surgery (months)

0,0

0,1

0,2

0,3

0,4

0,5

0,6

0,7

0,8

0,9

1,0

Cum

ulat

ive

Prop

ortio

n Su

rviv

ing

Weak FXYD-3 (n=106)

Strong FXYD-3 (n=23)

FXYD-3 expression No RT

RT

Weak (0,1,2) 46 (84%) 21 (81%)

Strong (3) 9 (16%) 5 (19%)

FXYD-3 expression

No RT RT

Weak (0,1,2) 23 (77%) 16 (89%)

Strong (3) 7 (23%) 2 (11%)

46

TheresultsfromstudyIindicatedthatFXYD-3couldpossiblyserveasaprognosticindicatorforsurvivalandalsoanindicatorofreducedradio-sensitivity.InmanylargestudiesradiotherapyhasreducedtheincidenceofLRbutitseffectonsurvivalisnotsoclear(1,80-83).ItwasthusourambitiontoanalyseFXYD-3expressionintumoursfromrectalcancerpatientsthatdevelopedalocalrecurrenceandtoseeifthesetumourshaveastrongFXYD-3expression,orifstrongFXYD-3expressionisrelatedtotimetoLR.ResearchersattheKarolinskaInstituteinStockholmhadpreviouslyperformedastudyonacohortofpatientsregardingtherelationshipofLRtoRT.IncooperationwiththeKarolinskaInstitutewedesignedthisstudyusingtheirformerstudycohort,whichalsomadeitpossibletoconfirmourresultsfromstudyIatanotherlaboratory. WewerenotabletoconfirmourfindingsofFXYD-3asaprognosticfactorforreducedsurvivaloranindicatorofradio-resistanceinthisstudy.Severalfactorscouldhavecontributedtothis;FirstlytherewerefewofthepatientsinboththeLRgroup(36%)andthecontrolgroup(31%)thatreceivedRT(Figure1).Thisincombinationwiththefactthatonly19%intheLRgroupand17%inthecontrolgrouphadstrongFXYD-3expressionsmadeithardtoreachstatisticallysignificantresults.Furthermore,patientsandcontrolswereonlymatchedforgenderandRTwhilebothtumourstageanddifferentiationdifferedbetweenthegroups.Immunohistochemistryisasemi-quantitativemethodandanalysisofoldformalinfixedspecimencouldwellbeanissuetoo.Blindedexaminationsofimmunohistochimistryslideswereperformedatbothhospitalstoensureobjectivegrading.Eventhoughseveralfindings,togetherandindependentlyfromthestudyIindicatedthatFXYD-3couldbeaprognosticfactorandanindicatorofreducedradio-sensitivity,theresultsofstudyIIIcouldnotsupportthis.Thecollectionofalargercohortofpatientswithlocalrecurrenceinordertogaingreaterpowerwouldbealargelong-termproject.Still,alargeprospectivecohortwithsamplesfrompreoperativebiopsiesanalysedwithRNAtechniqueswouldbeofinterestinthesearchforpredictivemarkersofreducedresponsetoneoadjuvanttreatment.

47

StudyIII.Completeeradicationoftheluminaltumour,ypT0wasfoundin161patients(8%).TheypT0rateincreasedwithdecreasingcT-stage,thehighestratebeingincT1-2cancers(Tables2-3).Theadditionofchemotherapyresultedin10%ypT0comparedto5.1%inthegroupwithoutchemotherapy(p<0.00004)ThelengthofdelaybetweenCRTandsurgerydidnotaffecttheypT0rateregardlessofwhetherLRTorSRTwithdelaywasused.OftheypT0patients83%hadtumour-negativeregionallymphnodes(ypT0N0),12%had1-3tumourpositivelymphnodes(ypT0N1)and4%hadmorethanthreetumourpositivelymphnodes(ypT0N2).ThedistributionofpNstatusdependedsignificantlyonthecN-status(p=0,000).Therewasasignificantlyreducedriskfortumour-positivelymphnodesinyoungerpatientsandincT1-2tumourscomparedtocT3-4(p=0.01).TherewassignificantlygreatersurvivalinypT0comparedtoypT+patients(hazardratio0.38(C.I0.25-0.58))andsurvivalwassignificantlygreaterinpatientswithypT0N0comparedtoypT0N1-2(hazardratio0.36(C.I0.15-0.86)).(Figure1)

Table1.Oddsratiosofcompleteresponse(ypT0)inclinicaltumourstagescT-stage Completeresponse(ypT0)(n,%) Oddsratio(CI)ofhavingCR* 161 8% cT1-2 21 14% 1cT3 77 9% 0.401(0.230-0.698)cT4 58 6% 0.227(0.125-0.413)cTX 5 2% 0.179(0.058-0.555)*Adjustedfor:age(under/over66yearsp=0.019),gender(0.081),tumourlevel(under/over8cmp=0.020),preoperativechemotherapy(yes/nop=0.001)andpreoperativeradiotherapy(Long-termradiotherapyvs.short-termradiotherapywithdelay(p=0.666)

48

Table2Luminalcompleteresponse(ypT0)inrelationtodifferentneoadjuvanttreatments.Luminalcompleteresponse(ypT0)inrelationtodifferentneoadjuvanttreatments.

Preoperative treatment

Long radiotherapy

(25x1.8/2Gy) and

preop.

chemotherapy

Long

radiotherapy

(25x1.8/2Gy)

Short

radiotherapy

(5x5Gy) and wait

>4 weeks and

preop.

chemotherapy

Short radiotherapy

(5x5Gy) and delay

>4 weeks

Total

Luminal complete

response

Luminal

complete

response

Luminal

complete

response

Luminal complete

response

Luminal

complete

response

No Yes No Yes No Yes No Yes No Yes

Clinical

T-

stages.

cT1-

cT2

14 6 8 0 3 3 108 12 133 21

70 % 30 % 100

%

0 % 50 % 50 % 90 % 10 % 86

%

14 %

cT3 304 45 79 6 70 8 368 18 821 77

87 % 13 % 93

%

7 % 90 % 10 % 95 % 5 % 91

%

9 %

cT4 533 43 74 4 69 7 174 4 850 58

92 % 8 % 95

%

5 % 91 % 9 % 98 % 2 % 94

%

6 %

cTX 41 2 14 1 2 0 32 1 89 4

95 % 5 % 93

%

7 % 100 % 0 % 97 % 3 % 96

%

4 %

Total 892 96 175 11 144 18 682 35 1893 160*

90 % 10 % 94

%

6 % 89 % 11 % 95 % 5 % 92

%

8 %

• InformationonclinicalT-stagesismissingforninepatients;oneofthemhadluminalcomplete

response.

49

Figure1cumulativesurvivalinrelationtoluminalcompleteresponseandnodalpathologystatus

Adjustedforadjuvantchemotherapyp=0000.HR(Noadjuvantchemotherapygiven):1.48(1.24-1.77)InthisregisterbasedstudywefoundalowypT0rate,(8%)comparedtootherstudiesthathaveshownratesof13-45%(84-86).OurresultsmayreflectthebroadinclusionofrectalcancerpatientsinSwedishnormalclinicalpracticewithahighproportionofT4tumoursandtheinclusionofpatientswithLRT,andSRTwithdelaybutwithoutchemotherapy.AsbothlocalandsystemicrecurrencesarereducedafterpCR(86-89)thesignificanceoftumourpositivenodesintheresectedspecimenisnotclear,buttheresultsofthisstudyindicateareductioninsurvivalinpatientswithypT0N1-2comparedtoypT0N0.Ourresultsshowthatthesurvivalbenefitfromcompleteresponseisdependentuponnodalinvolvement,witha survivalcurveforypT0N+similartothecurveforpatientswithypT+.WecouldnotconfirmpreviousfindingsofimprovedypT0rateswithincreaseddelaybetweenRTandsurgery(15).Therewas,howeveranarrowtimespanbetweenLRTandsurgeryforthegroupasawholeinthisstudyduetoadherencetoSwedishguidelines.Therationalebehindnon-surgicalmanagementisbasedontheclinicalabilitytoruleoutremainingtumourinthepelvis,includingtheregionallymphnodes.Aprerequisiteisthateventualregrowthcanbedetectedandtreatedwithresultsthatarenotinferiorto

HR :0.22(C .I.0.13-0.37)HR :0.54(C .I.0.47-0.63)HR :0.66(C .I.0.32-1.30)

Reference

Gehan's generaliz edWilcoxontes t,P -value= 0.0000

0year 1year 2year 4year 5year

pT0N0 133 132 119 85 91%(85%-97%) 63 38pT+N0 1052 1006 873 646 82%(80%-84%) 437 278pT0N+ 26 26 23 12 74%(56%-92%) 10 7

pT+N+ 817 763 596 391 67%(63%-71%) 237 131

3yearP atientsa trisk/ac tua l3-yearsurviva l(95%C .I.)

50

surgery.Foradvancedtumourstheriskforlymphnodemetastasesdespiteluminalcompleteresponseishighandthisstudyindicatesalessfavorableprognosisevenwithradicalsurgery.TheprognosisforpatientswithpT0N+issignificantlyworsethanforpT0N0evenwithradicalsurgery.Wealsofoundthatchemotherapyseemstohavelittleeffectonlymphnodemetastases.Whenconsideringa“watchfulwaiting”policythesefindingsshouldbetakenintoaccount.

51

StudyIV.Thirty-eightpatientswereevaluated,19withypT0N0and19withypT0N+.Themeantimebetweenpost-CRTMRIstagingandsurgerywas21days(6-68)withnostatisticaldifferencebetweentheN0andN+group(21and25daysp=0.27).Atthepre-CRTMRIstagingatotalnumberof314lymphnodesweredetected,and122(39%)oftheseweresuspectedtobemalignant.TheaveragenumberoflymphnodesintheypN0groupwas9andintheypN+group7(p=0.5).(Figure1).TheaveragesizeofthelymphnodesintheypN0groupwas4.0mmandintheypN+groupitwas3.8mm(p=0.65).Thetotalsumofsizeswas645and612mmrespectively(p=0.81).Atpost-CRTMRIstaging,107lymphnodesweredetectedand20(19%)oftheseweresuspectedtobemalignant.Twenty-nineoutof38patientshadnosuspectedmalignantnode.Onaveragetherewere2.7nodesdetectedintheypT0groupcomparedto2.9nodesintheypT+group(p=0.75)(Figure1).TheaveragelymphnodesizeintheypT0N0groupwas1.9mmand3.0mmintheypT0N+group(p=0.12).Thetotalsumofsizewas144and225mmrespectively(p=0.21).

WhencomparingtheaveragesizeofthelargestnodeforallpatientstherewasasignificantdifferencebetweentheypN0andypN+groups(2.6mmvs.4.5mm)(p=0.04)(Figure2).Nodeslargerthan8mmwereonlyfoundinN+patients(n=3).TwopatientswithnolymphnodedetectedonMRIstagingwerestagedypN+atthepathologyreport.Ofthe19patientswhowereypN+12wereMRIstagedasN0,and3ofthe19ypN0werestagedasN+.Sensitivity,specificity,PPVandNPVfortheexpertradiologiststocorrectlydetectlymphnodemetastasesinypT0patientswere37%,84%,70%and55%respectively.

Sizeandmorphologytogetherarethetwomostpromisinglymphnodefeaturesusedtodiscriminatebetweenmalignantandbenignnodes.Westillneedtofindathresholdvaluethatcanruleoutmalignantlymphnodesbysizealone.Thecut-offsizeisprobablyrelatedtopopulationfactorssuchasinitialtumourstage,CRTregimenandthetimebetweenCRTtreatmentandreevaluationMRI.TheresultsofthisstudyonypT0andlymphnodestagingshowsthatCRThasasubstantialeffectonthesizeandnumberoflymphnodesdetected.Thesmallnumbersofpatients,causingaType2errormadeithardtofindsignificantchangesbetweenthetwogroups.Withregardtosuspectedmalignantlymphnodes,wecouldseeatrendtowardstherebeingmoresuspectlymphnodesbothbeforeandafterCRTintheypT0N+group(Fig1).Furthermoretherewasnosignificantdifferenceinsizeofnodesbetweenthetwogroupsandwhichisincontrasttootherstudies(61,90).Weexcludedallbutcompleterespondersinourstudypopulationincontrasttootherstudies,whichcomprisedagreatervarietyinpostCRTT-stage.WhenweanalyzedtheaveragesizeofthelargestlymphnodewefoundthattheypT0N+grouphadasignificantlylargerparamountglandthantheypT0N0group.ThismayindicateN+stageinLCR.ThisisoneofthefirststudiesonluminalcompleteresponseandlymphnoderestagingbyMRI.Weshowedalargereductioninbothsuspectedmalignantandbenign-lookinglymphnodesafterCRT.Thesizeofthelargestlymphnodeseemedtopredictnodemalignancy.TheresultsofthisstudyindicatetheneedforabettermethodtoadequatelypredictlymphnodestatusinpatientswithluminalcompleteresponseafterCRTinrectalcancer.

52

Figure1.DetectedlymphnodesinrelationtoN-stage

Figure2.AveragesizeofthelargestlymphnodeinrelationtoN-stage.

173

141

51 5641

81

416

020406080100120140160180200

ypT0N0 ypT0N+

PreCRTMRItotalnumberoflymphnodes

PostCRTMRItotalnumberoflymphnodes

PreCRTMRIsuspectedlymphnodes

PostCRTMRIsuspectedlymphnodes

7,17,9

2,6

4,5

0

1

2

3

4

5

6

7

8

9

ypT0N0 ypT0N+

mm

PreCRTMRIaveragelargestlymphnode.(p>0.05)

PostCRTMRIaveragelargestlymphnode.(p=0.04)

53

GeneraldiscussionandfutureperspectivesAfterClaudeDixon’sdevelopmentoftheanteriorresectionin1948(52)littlehappenedinrectalcancertreatmentforalmostfortyyearsuntilthemid1980’swithboththedevelopmentofTMEsurgeryandperioperativeradiotherapy(53,54).Duringtheyearsfollowingtherewasarapidevolutioninrectalcancertreatmentwithneoadjuvantandadjuvantchemotherapy,laparoscopy,enhancedrecoveryprogrammes,multidisciplinaryteamconferences,non-operativemanagementandroboticsurgery(43,45,57).Allthesemeasuresaimedatimprovingpatientoutcomeandminimizingmorbidity.Inoureffortstomaximizetheeffectsofantitumourtreatmentsthereisalwaystheriskthatthosepatientsnotresponding,gainnothingandenduppayingthepriceofside-effectsandalongertimewaitingforcurativetreatment.ItisthereforeimportanttofindindicatorsthatpredictorindicateresponsetoCRTtreatmentinperioperativeoncologicalmanagement.InstudyIweinvestigatedtheproteinFXYD-3thattheoreticallycouldserveasanindicatorofmalignantprogression.OurresultsshowedthattumourswithincreasedFXYD-3expressionshowedlessnecrosisafterRTandmoreinfiltrativegrowthcoupledwithreducedsurvival.ThissuggestedthatFXYD-3couldbeapredictorofreducedsurvivalasaresultoflowerradio-sensitivity.ToconfirmthesefindingswedesignedstudyIIonFXYD-3expressionrelatedtolocalrecurrencewherewecoulddirectlypinpointtheactualissueonradiosensitivity.Wealsoattemptedtoconfirmourfindingsbycomparisonofimmunohistochemistryresults,asemi-quantitativemethodatanotherrenownedcenter,(KarolinskaInstitue).InstudyIInoneofthefindingsfromstudyIonthespecificissuesofradio-sensitivityandlocalrecurrenceduetoover-expressionofFXYD-3couldbeconfirmed.ThismaybeduetothefactthatthereisnorelationshipbetweentheexpressionofFXYD-3andlocalrecurrence,itcouldalsobethatwedidnothavethestatisticalpowertoproveit.InconclusionthesignificanceofFXYD-3expressioninrectalcancerisstillnotclear.Theparadigmofnon-operativemanagementofrectalcancerwaspioneeredinBrazil(91).Culturaldifferencesmaytriggerandpropelsurgicaldevelopmentinonepartoftheworldthatwouldprobablynothaveevolvedinotherplaces.Oneexampleisthegeneralviewregardingstomas,wherebothsurgeonsandpatientsinnorthernEuropeseemtohaveamorepermissiveviewthanthosefromsouthernEuropeorSouthAmerica.Thisisprobablyreflectedintherateofcoloanalanastomosesandinverselyintherateofpermanentstomas(92).Culturaldifferenceslikethiscouldhavebeenacontributingfactorwhytheconceptofnon-operativemanagementwasfirstexploredinBrazil(12,13,91).Inthecaseofcompleteresponsewithabsenceofcancercellsintherectum,itisevenharderforapatienttoacceptapermanentstoma.Whennewtreatmentoptionsandtherapiesdevelopincentersoutsidethenationalwelfaresystem,conclusionsregardingtheeffectsofanewparadigmatthenationallevelaredifficulttodraw.Largenationalregisterscanbeusedtovalidatedatafromsmallcentersbyidentifyinglowfrequencyside-effects,aswellasculturaldifferencesinoutcomeandindications(69).InstudyIIIweaimedtoinvestigatetherateofcompletepathologicalresponseusingdatafromanationalregister.Wefoundalowrateofcompleteresponsecomparedtoothersingle-centerstudies(11,13,91),butourresultsreflectanolderpopulationwith

54

moreadvancedtumourstagesandtreatmentwithnointenttoachievecompleteresponseperse.Thefindingsofarelativelyhighrateofremainingtumourpositivelymphnodesinthesurgicalspecimenreflectedbyalowersurvivalrateisprobablyaconsequenceofthehighproportionofadvancedtumoursinourstudy.Thisstressestheimportanceofcarefulrestagingandpatientselectionwhenconsideringanon-operativemanagement.Inordertomakewell-foundeddecisionsonnon-operativemanagementthereisaneedtovalidatemethodsusedforrestagingafterneoadjuvanttreatment.InstudyIVwecametotheconclusionthatdespiteassessmentbyexpertradiologists,presentMRItechniqueseemnottobeadequateenoughtodiscriminatebetweenbenignandmalignantlymphnodes.Thisisafindingthatisinlinewithpreviousresearch(93).UnfortunatelyMRIisthebestwehaveinclinicalpracticeatthemoment.Thesearchfornewpredictorsofresponsetoneoadjuvantoradjuvanttreatmentwillgoon.Sofartherehasbeenmuchresearchbutwithdismalresults,whichleadsustobelievethatitwilltaketimebeforeapredictorofresponsetoneoadjuvanttreatmentcomesintoclinicaluse(9).Non-operativemanagementofrectalcancerwillprobablyhaveamajorimpactonfuturemanagement.Theconceptofneoadjuvanttreatmentusingonlychemotherapywillprobablycontinuetodevelop.Withearlyfulldosechemotherapywecanbeabletotreatmicro-metastaticdiseaseandatthesametimeomittingradiotherapywithitslong-termsideeffects.Althoughdatafromlargeprospectivestudiesisstilllacking. AstherateofbothlocalanddistantrecurrenceisreducedwithcompleteresponsetoCRT,outcomewillbeimproved(11,13,87).Ifthatholdstrueinnon-operativemanagement,rectalcancertreatmentwillundergomajorchangesinthenearfuture.Furthermorelong-termfollow-upanditsimpactonthehealthcaresystemanditsresources,andpatientconcernabouthavingtolivewithalife-longdiagnosisofcancerareissuesthatmustbediscussed.Withourpresentgoalofdevelopingdiagnostictoolsthatarenotdependentonionizingraytechniques,wewillcertainlyseerapidimprovementsinMRItechnologyinthenearfuture.Iaminterestedtocontinuetheresearchoncompleteresponseinrectalcancerinthefuture.Ibelieveitwouldbesafertoselectpatientsforanon-operativemanagementifwecouldbetteridentifypatientsatriskofhavingaregrowthoftheluminaltumourordevelopingmetastaticdisease.PresenceoftumourpositivelymphnodesafterCRTseemstobeariskfactorforreducedsurvival.ItisunfortunatelydifficulttoidentifythesetumourpositivelymphnodesafterCRTbyusingMRIonly.IwouldliketofurtheranalyzethefindingsfromstudyIVwherethesizeofthelargestlymphnode(4,5mm)seemedtoindicateN+stage.Ofinterestisthatthesizeof4.5mmalsohasbeensuggestedascut-offsizeforidentifyingmalignantnodesafterCRTinanotherstudy(61).Wehaveinitiatedaplanforastudywherewewouldidentifyandfollow-uppatientswhodevelopeddistantmetastasesafterCRTinoperatedrectalcancer.InitiallyweplantoretrospectivelyanalyzetherestagingMRIimagesandmeasurethesizeofthelargestlymphnode.Wewouldthenanalyzeifthereisacorrelationbetweenthesizeofthelargestlymphnodeandthedevelopmentofdistantmetastases.Acontrolgroupwiththesametreatmentbutnometastaseswouldbeusedforcomparison.Ifwecouldconfirmthatthesizeofthelargestlymphnodecorrelatestoreducedsurvivalitcouldindicateasentinelnodefunctioninrectalcancer.Identificationofasinglelargeindexlymphnode

55

asanindicatorforN+stagewouldbemorereproduciblethanmorphologiccriteriaofindividuallymphnodes.Wecouldusethispilot-studyforafuturelargerprospectivestudy.Inthatstudywecouldincludeotherfactorssuchasextra-muralvascularinvasion(EMVI)andtumourregression.Thesefactorscouldthenbeanalyzedandcomparedtooutcomeinordertosaferselectpatientsforanon-operativemanagementofrectalcancer.

56

57

AcknowledgementsTherearesomany thatdirectlyor indirectlyhavesupportedme through thisexcitingjourney. It isnotpossible to thankallofyou individuallybut Iammostgratefuland IthankyouallforallthehelpandsupportIhavereceived.Afewpersonsmustbementioned,aswithoutthemthisthesiswouldnothaveseenthelightofday.Olof Hallböök,mymain tutor, colleague, professor and friendwho has been a hugesource of knowledge and inspiration for me, both in research and daily surgical life.Longhoursofsurgerywithashortbreakforfoodandresearchdiscussion,thebetteroftwoworlds!Withgreatpatiencepushingmewhennecessarybutalwayssupportingmeand finding time for discussions despite tough schedules and grouchy section leader.YouhavealwaysbeentherefromthebasementofGrandCentralStationinNewYorktotheroofofIlDuomoDiMilano.Ihopewecanlookforwardtofutureprojectsandthatyou´llkeeppushingmetokeep“attentiontodetails”asIamnotreallythereyet…Xiao-FengSun,professorandmyfirsttutorwhotookmeonwhenIknewabsolutelynothingaboutresearchandevenlessoflabwork.Youtaughtmescientificwriting, labwork and all the other tricks of the trade in research. You were always extremelygenerous in sharingwithmeyour time andyourdeepknowledge.Without your kindand professional introduction to research I would probably have left the lab andreturnedbacktotheoperationtheatre,butIamverythankfulthatyoushowedmetheroadtoresearch.Gunnar Arbman, co-tutor and long-time colleague inNorrköping. Who alsowasmyfirsthead-of-thedepartment,andtheonewhoinspiredmetogoontoresearchusinghisuniqueregisterdata.MyintentionwastocombineyourclinicalexpertiseanddatawithXiao-Feng’smolecularknowledgeandlab.Asitturnedoutthatjobisstillnotdone!Your contribution to this thesis has been invaluable.With your laser-sharpmind youalwayscamewithaquickresponseandcrystalclearremarksregardingnewmaterial.Andnomatterhowmanytimes therestofusreadandrereadamanuscript, ithad topass through Gunnar’s hands before we could trust in it. I am very grateful foreverythingyouhavetaughtmeinsurgeryandscience.JohanDabrosinSöderholm,professor,forashortbutveryimportantperiodmymaintutor. You navigated through dire straits and put me in contact with people at theKarolinskaIntsituteandmadesurethattheshowwenton.IamverygratefulJohan.Victoria Fomichov, co-author and statistician. The process of boiling down 11226patients to the 26 that we were really interested in would not have been possiblewithoutadedicated,brightstatisticianwithvastexperience incancerregisters. Ihadone!Iamsurethatforawhileyouthought(orstilldo)thatthepersonwhosentyoue-mailquestionsonstatisticsandmethodswasatenyear-oldkidonhisfather’scomputer.Itwouldhavebeenfuntokeeponresearchingwithyou,butIthankyouforyoureffortsandwishyouthebestofluckwithyournewjob.

58

TheKarolinskateamI,DavidEdler,ErikSyk,PelleNilsson,andMarjaHallström.I amverygrateful forour cooperationon the2ndarticleand forwelcomingme to thefantasticteamsfromKarolinskaandErsta.Indifferentwaysyouhaveall inmadeveryimportantcontributions,butmostofallbyyourgenerositywithtimeandrecoursesandnot the least, patience. It ‘s always great to meet you at different surgical meetingswhereyoualwaystreatmeasifIwasa08!KarolinskaTeamII,ProfessorLennartBlomqvistandMargrétSturludottir,whentreadingonthiniceasasurgeoni.e.writinganarticleonMRIinterpretationyouneedsomeonetoholdonto.Lennartisaninternationalauthorityinthisfield.Iamextremelygrateful tohavebeenworkingwithyouandMargréton the4th article.Youhavebothmadeaverylargeandimportantcontributionandithasbeenaneye-openertositanddiscuss MRI set ups and interpretations with you. Without radiology we are blindwithoutradiologistswearelost.KarinAlmlöv,co-authorwhodidagreatjobwithfigures,numbersandpatientsinthe4tharticle,itisgreatfuntoworkwithyouandIhopewecancontinue.AnnaLindhoffLarssonandMalinOhlsson,researchnurseswhohavehelpedmewiththetediousworkofnaggingatotherhospitalstosenduspatientrecords,andMRIfiles.Nottomentionsortingthemoutintoperfectorder.Youhavebeenagreathelp.Peter Cox, not only an outstanding anesthesiologist but also a master of both theSwedishandEnglishlanguagewhonotonlyhelpedmedwithlanguageeditingbutwhoalso had many interesting questions and ideas about my research, which was veryrefreshing.Itisalwaysthesamepleasuretoworkwithyouontextsorinsurgery.NinaLönn,who tookmylongtimeratherblurryvisualideaoftheWaronCancerandturneditintoaworkofartonthecoverofthisbook.ThisisprobablytheonlythinginthisprocessthatendedupthewayIthoughtsixyearsagointhisprocess.Allmycolleagues,nursesandstaffattheDepartmentofSurgery,Linköpingwhohavereallymademefeelwelcome.Thecolorectalunit,OlofHallböök,DisaKalman,BärbelJung,AndersKald,PärMyrelid,HannaLjungbåge,EleonorAhlgrenandAnnaLevinandallthenurseswhoallmakeaperfectteamandwhohavesupportedmeallthewayinbothresearchandclinicalday-to-daylifesharingyourexperienceandfriendship.Iwillbeback!AllmycolleaguesandfriendsattheDepartmentofSurgeryinNorrköpingwhoformanyyearshavesupportedmeandincludedmeinawonderfulsurgicalteam.Afewindividualsmustbementionedthough,GunnarIhavementionedbefore,StaffanHaapaniemimylong-timepartnerinsurgerywhoinspiredmetodoresearchandcoveredformewhileIdelvedintobooks.HasseKrook,headofthedepartmentformanyyearswhoencouragedmetotaketheleapintoresearch.Thefantasticcolorectalnurses,whomadesurgicallifesomucheasier.Alltheresidents,severalofwhomhavemanagedtobecomeexcellentcolorectalsurgeonsduringthetimeittookmetowritethisbook,keeponpushing!

59

PerSandström,Professorforeditingandreadingmythesisandsharingyourexperienceonresearchwithme.

RuneSjödahl,professorwhohasbeenaninspirationinsurgery,leadershipandresearch.Ihavefeltyoursupportandinterestinmyresearchfromearlyon.Katarina,Kärling,TeresErwillandGunillaLinghammar.Greatgang,oneofyouwon’tmissme!ConnyWallon,headoftheDepartmentofSurgeryinLinköpingwhohastrustedandsupportedmeinclinicalwork,andhasmadethisthesispossiblebyallocatingtime,givingencouragementandbysteppingintohelpwithclinicalworkwheneveryouhadtheopportunitydespiteanoverbookedschedule.Allfriendswhohavepushedandsupportedandhelpedwheneverhelpwereneededinabusyfamilyschedule.TheCösterandPompermaier/WijkmanfamiliesaswellastheAldrinfamily,youhaveallbeenpartofthisjourneyandbeenimportantsupportforourfamily.JulieWilkandJonasMalmstedtforfriendshipandtheinspirationtoresearch.HannaandJohanBjörkdahl-Loftås.Foreverythingalltheway!MayLisandStigLoftås,wonderfulparentswhobroughtmeuptobelieveinmyselfnomatterwhat,andalwaysinspiredandsupportedmyfamilyandI.OnlyyoucouldhavebelievedIwouldenduphere,Iamsogratefultoyou,andmysistersSaraandAnnforbeingthebestfamilyonecouldaskfor.Aboveall-Lindamybelovedwife.Onlyyouknowwhatyouhavedonetohelpmethroughthis,andIloveyouforthat,andeverythingelse.Trustme,thereisalifeafterthisanditwillbegreattoliveitwithyou.Hanna,Ida,YlvaandEmil,wonderfulkidsthatgivemesomuchjoyandlaughtereveryday.Youhelpmegoon!

60

61

References

1. GlimeliusB,GronbergH,JarhultJ,WallgrenA,Cavallin-StahlE.Asystematicoverviewofradiationtherapyeffectsinrectalcancer.ActaOncol.2003;42(5-6):476-92.2. SwedishRectalCancerRegistry.Årsrapport2016[Internet].2016.3. BossetJF,ColletteL,CalaisG,MineurL,MaingonP,Radosevic-JelicL,etal.Chemotherapywithpreoperativeradiotherapyinrectalcancer.NEnglJMed.2006;355(11):1114-23.4. CeelenWP,VanNieuwenhoveY,FierensK.PreoperativechemoradiationversusradiationaloneforstageIIandIIIresectablerectalcancer.TheCochranedatabaseofsystematicreviews.2009(1):CD006041.5. BirgissonH,PahlmanL,GunnarssonU,GlimeliusB.Lateadverseeffectsofradiationtherapyforrectalcancer-asystematicoverview.ActaOncol.2007;46(4):504-16.6. PfeiferD,GaoJ,AdellG,SunX.Expressionofthep73proteininrectalcancerswithorwithoutpreoperativeradiotherapy.InternationalJournalofRadiationOncologyBiologyPhysics.2006;65(4):1143-8.7. PfeiferD,WallinÅ,HolmlundB,SunX-F.Proteinexpressionfollowingγ-irradiationrelevanttogrowtharrestandapoptosisincoloncancercells.JournalofCancerResearchandClinicalOncology.2009;135(11):1583-92.8. MolinariC,MatteucciF,CaroliP,PassardiA.BiomarkersandMolecularImagingasPredictorsofResponsetoNeoadjuvantChemoradiotherapyinPatientsWithLocallyAdvancedRectalCancer.ClinColorectalCancer.2015;14(4):227-38.9. KuremskyJG,TepperJE,McLeodHL.BiomarkersforResponsetoNeoadjuvantChemoradiationforRectalCancer.InternationalJournalofRadiationOncologyBiologyPhysics.2009;74(3):673-88.10. AgostiniM,CrottiS,BedinC,CecchinE,MarettoI,D'AngeloE,etal.Predictiveresponsebiomarkersinrectalcancerneoadjuvanttreatment.FrontBiosci(ScholEd).2014;6:110-9.11. Glynne-JonesR,HughesR.Criticalappraisalofthe'waitandsee'approachinrectalcancerforclinicalcompleterespondersafterchemoradiation.BrJSurg.2012;99(7):897-909.12. Habr-GamaA,PerezRO.Non-operativemanagementofrectalcancerafterneoadjuvantchemoradiation.BrJSurg.2009;96(2):125-7.13. Habr-GamaA,PerezRO,SãoJuliãoGP,ProscurshimI,Gama-RodriguesJ.NonoperativeApproachestoRectalCancer:ACriticalEvaluation.SeminarsinRadiationOncology.2011;21(3):234-9.14. MaasM,Beets-TanRG,LambregtsDM,LammeringG,NelemansPJ,EngelenSM,etal.Wait-and-seepolicyforclinicalcompleterespondersafterchemoradiationforrectalcancer.JClinOncol.2011;29(35):4633-40.15. SloothaakDA,GeijsenDE,vanLeersumNJ,PuntCJ,BuskensCJ,BemelmanWA,etal.Optimaltimeintervalbetweenneoadjuvantchemoradiotherapyandsurgeryforrectalcancer.BrJSurg.2013;100(7):933-9.16. PucciarelliS,BacigalupoL,MarettoI.Predictingresponsetoneoadjuvanttherapyforrectalcancer.Techniquesincoloproctology.2014;18(8):683-4.17. DedemadiG,WexnerSD.Completeresponseafterneoadjuvanttherapyinrectalcancer:tooperateornottooperate?DigDis.2012;30Suppl2:109-17.

62

18. LambregtsDM,MaasM,BakersFC,CappendijkVC,LammeringG,BeetsGL,etal.Long-termfollow-upfeaturesonrectalMRIduringawait-and-seeapproachafteraclinicalcompleteresponseinpatientswithrectalcancertreatedwithchemoradiotherapy.DisColonRectum.2011;54(12):1521-8.19. RajagopalanH,NowakMA,VogelsteinB,LengauerC.Thesignificanceofunstablechromosomesincolorectalcancer.NatRevCancer.2003;3(9):695-701.20. FearonER,VogelsteinB.Ageneticmodelforcolorectaltumorigenesis.Cell.1990;61(5):759-67.21. ArendsJW.MolecularinteractionsintheVogelsteinmodelofcolorectalcarcinoma.JPathol.2000;190(4):412-6.22. ParrisGE.Historicalperspectiveofcell-cellfusionincancerinitiationandprogression.CritRevOncog.2013;18(1-2):1-18.23. PrescottSM,WhiteRL.Self-promotion?IntimateconnectionsbetweenAPCandprostaglandinHsynthase-2.Cell.1996;87(5):783-6.24. GiardielloFM,HamiltonSR,KrushAJ,PiantadosiS,HylindLM,CelanoP,etal.Treatmentofcolonicandrectaladenomaswithsulindacinfamilialadenomatouspolyposis.NEnglJMed.1993;328(18):1313-6.25. AndoM,MaruyamaM,OtoM,TakemuraK,EndoM,YuasaY.Higherfrequencyofpointmutationsinthec-K-ras2geneinhumancolorectaladenomaswithsevereatypiathanincarcinomas.Japanesejournalofcancerresearch:Gann.1991;82(3):245-9.26. TannapfelA,NussleinS,FietkauR,KatalinicA,KockerlingF,WittekindC.Apoptosis,proliferation,bax,bcl-2andp53statuspriortoandafterpreoperativeradiochemotherapyforlocallyadvancedrectalcancer.IntJRadiatOncolBiolPhys.1998;41(3):585-91.27. ReedJC.Bcl-2andtheregulationofprogrammedcelldeath.JCellBiol.1994;124(1-2):1-6.28. BakerSJ,PreisingerAC,JessupJM,ParaskevaC,MarkowitzS,WillsonJK,etal.p53genemutationsoccurincombinationwith17pallelicdeletionsaslateeventsincolorectaltumorigenesis.Cancerresearch.1990;50(23):7717-22.29. LevineAJ.p53,thecellulargatekeeperforgrowthanddivision.Cell.1997;88(3):323-31.30. ThomasG.Advancesinthegeneticsandmolecularbiologyofcolorectaltumors.Currentopinioninoncology.1994;6(4):406-12.31. IlyasM,TomlinsonIP.TheinteractionsofAPC,E-cadherinandbeta-cateninintumourdevelopmentandprogression.JPathol.1997;182(2):128-37.32. BolandCR.Thebiologyofcolorectalcancer.Implicationsforpretreatmentandfollow-upmanagement.Cancer.1993;71(12Suppl):4180-6.33. JessupJM,GiavazziR,CampbellD,ClearyK,MorikawaK,FidlerIJ.Growthpotentialofhumancolorectalcarcinomasinnudemice:associationwiththepreoperativeserumconcentrationofcarcinoembryonicantigeninpatients.Cancerresearch.1988;48(6):1689-92.34. FolkmanJ.Tumorangiogenesisandtissuefactor.Naturemedicine.1996;2(2):167-8.35. JoinerM.Basicclinicalradiobiology:CRCPress;2009.36. BirgissonH,PahlmanL,GunnarssonU,GlimeliusB.Adverseeffectsofpreoperativeradiationtherapyforrectalcancer:long-termfollow-upoftheSwedishRectalCancerTrial.JClinOncol.2005;23(34):8697-705.

63

37. BirgissonH,PahlmanL,GunnarssonU,GlimeliusB.Occurrenceofsecondcancersinpatientstreatedwithradiotherapyforrectalcancer.JClinOncol.2005;23(25):6126-31.38. PetterssonD,CedermarkB,HolmT,RaduC,PåhlmanL,GlimeliusB,etal.InterimanalysisoftheStockholmIIItrialofpreoperativeradiotherapyregimensforrectalcancer.BritishJournalofSurgery.2010;97(4):580-7.39. PetterssonD,HolmT,IversenH,BlomqvistL,GlimeliusB,MartlingA.Preoperativeshort-courseradiotherapywithdelayedsurgeryinprimaryrectalcancer.BrJSurg.2012;99(4):577-83.40. LoftasP,ArbmanG,FomichovV,HallbookO.Nodalinvolvementinluminalcompleteresponseafterneoadjuvanttreatmentforrectalcancer.Europeanjournalofsurgicaloncology:thejournaloftheEuropeanSocietyofSurgicalOncologyandtheBritishAssociationofSurgicalOncology.2016;42(6):801-7.41. AppeltAL,PloenJ,VogeliusIR,BentzenSM,JakobsenA.Radiationdose-responsemodelforlocallyadvancedrectalcancerafterpreoperativechemoradiationtherapy.IntJRadiatOncolBiolPhys.2013;85(1):74-80.42. LawrenceTS1BA,McGinnC.Themechanismofactionofradiosensitizationofconventionalchemotherapeuticagents.SeminRadiatOncol.Jan;13(1):13-21.43. BolandPM,FakihM.Theemergingroleofneoadjuvantchemotherapyforrectalcancer.JGastrointestOncol.2014;5(5):362-73.44. PetersenSH,HarlingH,KirkebyLT,Wille-JorgensenP,MocellinS.Postoperativeadjuvantchemotherapyinrectalcanceroperatedforcure.TheCochranedatabaseofsystematicreviews.2012(3):CD004078.45. AscheleC,CioniniL,LonardiS,PintoC,CordioS,RosatiG,etal.Primarytumorresponsetopreoperativechemoradiationwithorwithoutoxaliplatininlocallyadvancedrectalcancer:pathologicresultsoftheSTAR-01randomizedphaseIIItrial.JClinOncol.2011;29(20):2773-80.46. AlGizawySM,EssaHH,AhmedBM.ChemotherapyAloneforPatientsWithStageII/IIIRectalCancerUndergoingRadicalSurgery.Theoncologist.2015;20(7):752-7.47. JalilO,ClaydonL,ArulampalamT.ReviewofNeoadjuvantChemotherapyAloneinLocallyAdvancedRectalCancer.Journalofgastrointestinalcancer.2015;46(3):219-36.48. LangeMM,RuttenHJ,vandeVeldeCJ.Onehundredyearsofcurativesurgeryforrectalcancer:1908-2008.Europeanjournalofsurgicaloncology:thejournaloftheEuropeanSocietyofSurgicalOncologyandtheBritishAssociationofSurgicalOncology.2009;35(5):456-63.49. MilesW.Amethodofperformingabdomino-perinealexcisionforcarcinomaoftherectumandoftheterminalportionofthepelviccolon(1908).TheLancet.1908(172(4451)):1812-3.50. NestorovicM.ONEHUNDREDYEARSOFMILES’OPERATION-WHATHASCHANGED?ActaMedicaMedianae.2008;47((4)):43-6.51. CirocchiR,FarinellaE,TrastulliS,DesiderioJ,DiRoccoG,CovarelliP,etal.Hightieversuslowtieoftheinferiormesentericartery:aprotocolforasystematicreview.WorldJSurgOncol.2011;9:147.52. DixonCF.AnteriorResectionforMalignantLesionsoftheUpperPartoftheRectumandLowerPartoftheSigmoid.Annalsofsurgery.1948;128(3):425-42.53. HealdRJ,HusbandEM,RyallRD.Themesorectuminrectalcancersurgery--thecluetopelvicrecurrence?BrJSurg.1982;69(10):613-6.

64

54. HealdRJ,RyallRD.Recurrenceandsurvivalaftertotalmesorectalexcisionforrectalcancer.Lancet.1986;1(8496):1479-82.55. EmmertsenKJ,LaurbergS.Lowanteriorresectionsyndromescore:developmentandvalidationofasymptom-basedscoringsystemforboweldysfunctionafterlowanteriorresectionforrectalcancer.Annalsofsurgery.2012;255(5):922-8.56. MoghadamyeghanehZ,PhelanM,SmithBR,StamosMJ.OutcomesofOpen,Laparoscopic,andRoboticAbdominoperinealResectionsinPatientsWithRectalCancer.DisColonRectum.2015;58(12):1123-9.57. BiffiR,LucaF,BianchiPP,CenciarelliS,PetzW,MonsellatoI,etal.Dealingwithrobot-assistedsurgeryforrectalcancer:Currentstatusandperspectives.Worldjournalofgastroenterology.2016;22(2):546-56.58. KohDM,BrownG,HusbandJE.Nodalstaginginrectalcancer.Abdominalimaging.2006;31(6):652-9.59. KohDM,BrownG,TempleL,BlakeH,RajaA,ToomeyP,etal.Distributionofmesorectallymphnodesinrectalcancer:invivoMRimagingcomparedwithhistopathologicalexamination.Initialobservations.Europeanradiology.2005;15(8):1650-7.60. GroupMS.Extramuraldepthoftumorinvasionatthin-sectionMRinpatientswithrectalcancer:resultsoftheMERCURYstudy.Radiology.2007;243(1):132-9.61. HeijnenLA,MaasM,Beets-TanRG,BerkhofM,LambregtsDM,NelemansPJ,etal.Nodalstaginginrectalcancer:whyisrestagingafterchemoradiationmoreaccuratethanprimarynodalstaging?IntJColorectalDis.2016;31(6):1157-62.62. BrownG,RichardsCJ,BourneMW,NewcombeRG,RadcliffeAG,DallimoreNS,etal.Morphologicpredictorsoflymphnodestatusinrectalcancerwithuseofhigh-spatial-resolutionMRimagingwithhistopathologiccomparison.Radiology.2003;227(2):371-7.63. DeNardiP,CarvelloM.Howreliableiscurrentimaginginrestagingrectalcancerafterneoadjuvanttherapy?Worldjournalofgastroenterology.2013;19(36):5964-72.64. HeijnenLA,LambregtsDM,MondalD,MartensMH,RiedlRG,BeetsGL,etal.Diffusion-weightedMRimaginginprimaryrectalcancerstagingdemonstratesbutdoesnotcharacteriselymphnodes.Europeanradiology.2013;23(12):3354-60.65. BooneD,TaylorSA,HalliganS.DiffusionweightedMRI:overviewandimplicationsforrectalcancermanagement.ColorectalDis.2013;15(6):655-61.66. Improvedsurvivalwithpreoperativeradiotherapyinresectablerectalcancer.SwedishRectalCancerTrial.NEnglJMed.1997;336(14):980-7.67. SykE,GlimeliusB,NilssonPJ.Factorsinfluencinglocalfailureinrectalcancer:analysisof2315patientsfromapopulation-basedseries.DisColonRectum.2010;53(5):744-52.68. SykE,LenanderC,NilssonPJ,RubioCA,GlimeliusB.Tumourbuddingcorrelateswithlocalrecurrenceofrectalcancer.ColorectalDis.2011;13(3):255-62.69. PahlmanL,BoheM,CedermarkB,DahlbergM,LindmarkG,SjodahlR,etal.TheSwedishrectalcancerregistry.BrJSurg.2007;94(10):1285-92.70. KimJH,BeetsGL,KimMJ,KesselsAG,Beets-TanRG.High-resolutionMRimagingfornodalstaginginrectalcancer:arethereanycriteriainadditiontothesize?Europeanjournalofradiology.2004;52(1):78-83.71. AnderleP,RakhmanovaV,WoodfordK,ZerangueN,SadeeW.MessengerRNAexpressionoftransporterandionchannelgenesinundifferentiatedand

65

differentiatedCaco-2cellscomparedtohumanintestines.Pharmaceuticalresearch.2003;20(1):3-15.72. BibertS,RoyS,SchaerD,Felley-BoscoE,GeeringK.StructuralandFunctionalPropertiesofTwoHumanFXYD3(Mat-8)Isoforms.JournalofBiologicalChemistry.2006;281(51):39142-51.73. KayedH,KleeffJ,KolbA,KettererK,KelegS,FelixK,etal.FXYD3isoverexpressedinpancreaticductaladenocarcinomaandinfluencespancreaticcancercellgrowth.Internationaljournalofcancer.2006;118(1):43-54.74. MorrisonBW,MoormanJR,KowdleyGC,KobayashiYM,JonesLR,LederP.Mat-8,anovelphospholemman-likeproteinexpressedinhumanbreasttumors,inducesachlorideconductanceinXenopusoocytes.TheJournalofbiologicalchemistry.1995;270(5):2176-82.75. VaaralaMH,PorvariK,KyllonenA,VihkoP.DifferentiallyexpressedgenesintwoLNCaPprostatecancercelllinesreflectingchangesduringprostatecancerprogression.Laboratoryinvestigation;ajournaloftechnicalmethodsandpathology.2000;80(8):1259-68.76. MaxwellPJ,LongleyDB,LatifT,BoyerJ,AllenW,LynchM,etal.Identificationof5-fluorouracil-inducibletargetgenesusingcDNAmicroarrayprofiling.Cancerresearch.2003;63(15):4602-6.77. BardelliA,SahaS,SagerJA,RomansKE,XinB,MarkowitzSD,etal.PRL-3expressioninmetastaticcancers.ClinCancerRes.2003;9(15):5607-15.78. LiuSS,LeungRC,ChanKY,ChiuPM,CheungAN,TamKF,etal.p73expressionisassociatedwiththecellularradiosensitivityincervicalcancerafterradiotherapy.ClinCancerRes.2004;10(10):3309-16.79. WallinAR,SvanvikJ,AdellG,SunXF.ExpressionofPRLproteinsatinvasivemarginofrectalcancersinrelationtopreoperativeradiotherapy.IntJRadiatOncolBiolPhys.2006;65(2):452-8.80. BujkoK,KolodziejczykM,Nasierowska-GuttmejerA,MichalskiW,KepkaL,ChmielikE,etal.Tumourregressiongradinginpatientswithresidualrectalcancerafterpreoperativechemoradiation.RadiotherOncol.2010;95(3):298-302.81. GlimeliusB,IsacssonU,JungB,PahlmanL.Radiotherapyinadditiontoradicalsurgeryinrectalcancer:evidenceforadose-responseeffectfavoringpreoperativetreatment.IntJRadiatOncolBiolPhys.1997;37(2):281-7.82. GrafW,DahlbergM,OsmanMM,HolmbergL,PahlmanL,GlimeliusB.Short-termpreoperativeradiotherapyresultsindown-stagingofrectalcancer:astudyof1316patients.RadiotherOncol.1997;43(2):133-7.83. HolmT,RutqvistLE,JohanssonH,CedermarkB.Postoperativemortalityinrectalcancertreatedwithorwithoutpreoperativeradiotherapy:causesandriskfactors.BrJSurg.1996;83(7):964-8.84. BujkoK,NowackiMP,Nasierowska-GuttmejerA,MichalskiW,BebenekM,KryjM.Long-termresultsofarandomizedtrialcomparingpreoperativeshort-courseradiotherapywithpreoperativeconventionallyfractionatedchemoradiationforrectalcancer.BrJSurg.2006;93(10):1215-23.85. HartleyA,HoKF,McConkeyC,GehJI.Pathologicalcompleteresponsefollowingpre-operativechemoradiotherapyinrectalcancer:analysisofphaseII/IIItrials.TheBritishjournalofradiology.2005;78(934):934-8.86. MaasM,NelemansPJ,ValentiniV,DasP,RodelC,KuoLJ,etal.Long-termoutcomeinpatientswithapathologicalcompleteresponseafterchemoradiationfor

66

rectalcancer:apooledanalysisofindividualpatientdata.TheLancetOncology.2010;11(9):835-44.87. CapirciC,ValentiniV,CioniniL,DePaoliA,RodelC,Glynne-JonesR,etal.Prognosticvalueofpathologiccompleteresponseafterneoadjuvanttherapyinlocallyadvancedrectalcancer:long-termanalysisof566ypCRpatients.IntJRadiatOncolBiolPhys.2008;72(1):99-107.88. VecchioFM,ValentiniV,MinskyBD,PadulaGD,VenkatramanES,BalducciM,etal.Therelationshipofpathologictumorregressiongrade(TRG)andoutcomesafterpreoperativetherapyinrectalcancer.IntJRadiatOncolBiolPhys.2005;62(3):752-60.89. MartinST,HeneghanHM,WinterDC.Systematicreviewandmeta-analysisofoutcomesfollowingpathologicalcompleteresponsetoneoadjuvantchemoradiotherapyforrectalcancer.BrJSurg.2012;99(7):918-28.90. KimIK,KangJ,LimBJ,SohnSK,LeeKY.Theimpactoflymphnodesizetopredictnodalmetastasisinpatientswithrectalcancerafterpreoperativechemoradiotherapy.IntJColorectalDis.2015;30(4):459-64.91. Habr-GamaA,PerezRO,NadalinW,SabbagaJ,RibeiroU,SilvaeSousaAH,etal.OperativeVersusNonoperativeTreatmentforStage0DistalRectalCancerFollowingChemoradiationTherapy.TransactionsoftheMeetingoftheAmericanSurgicalAssociation.2004;CXXII(&NA;):309-16.92. HolzerB,MatzelK,SchiedeckT,ChristiansenJ,ChristensenP,RiusJ,etal.Dogeographicandeducationalfactorsinfluencethequalityoflifeinrectalcancerpatientswithapermanentcolostomy?DisColonRectum.2005;48(12):2209-16.93. MemonS,LynchAC,BresselM,WiseAG,HeriotAG.Systematicreviewandmeta-analysisoftheaccuracyofMRIandendorectalultrasoundintherestagingandresponseassessmentofrectalcancerfollowingneoadjuvanttherapy.ColorectalDis.2015;17(9):748-61.

Papers

The articles associated with this thesis have been removed for copyright

reasons. For more details about these see:

http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-132759